ID   EP300_HUMAN             Reviewed;        2414 AA.
AC   Q09472; B1AKC2;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   10-FEB-2009, sequence version 2.
DT   10-MAY-2017, entry version 220.
DE   RecName: Full=Histone acetyltransferase p300;
DE            Short=p300 HAT;
DE            EC=2.3.1.48 {ECO:0000269|PubMed:23415232, ECO:0000269|PubMed:23934153, ECO:0000269|PubMed:8945521};
DE   AltName: Full=E1A-associated protein p300;
GN   Name=EP300; Synonyms=P300;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT PRO-2223.
RX   PubMed=7523245; DOI=10.1101/gad.8.8.869;
RA   Eckner R., Ewen M.E., Newsome D., Gerdes M., Decaprio J.A.,
RA   Lawrence J.B., Livingston D.M.;
RT   "Molecular cloning and functional analysis of the adenovirus E1A-
RT   associated 300-kD protein (p300) reveals a protein with properties of
RT   a transcriptional adaptor.";
RL   Genes Dev. 8:869-884(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 27-42, AND CHROMOSOMAL TRANSLOCATION
RP   WITH KAT6A.
RX   PubMed=10824998;
RX   DOI=10.1002/(SICI)1098-2264(200006)28:2<138::AID-GCC2>3.0.CO;2-2;
RA   Chaffanet M., Gressin L., Preudhomme C., Soenen-Cornu V., Birnbaum D.,
RA   Pebusque M.-J.;
RT   "MOZ is fused to p300 in an acute monocytic leukemia with t(8;22).";
RL   Genes Chromosomes Cancer 28:138-144(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 552-660.
RX   PubMed=7870179; DOI=10.1038/374085a0;
RA   Lundblad J.R., Kwok R.P.S., Laurance M.E., Harter M.L., Goodman R.H.;
RT   "Adenoviral E1A-associated protein p300 as a functional homologue of
RT   the transcriptional co-activator CBP.";
RL   Nature 374:85-88(1995).
RN   [6]
RP   PARTIAL PROTEIN SEQUENCE, INTERACTION WITH CARM1, METHYLATION AT
RP   ARG-580 AND ARG-604, AND FUNCTION.
RX   PubMed=11701890; DOI=10.1126/science.1065961;
RA   Xu W., Chen H., Du K., Asahara H., Tini M., Emerson B.M., Montminy M.,
RA   Evans R.M.;
RT   "A transcriptional switch mediated by cofactor methylation.";
RL   Science 294:2507-2511(2001).
RN   [7]
RP   CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=8945521; DOI=10.1016/S0092-8674(00)82001-2;
RA   Ogryzko V.V., Schiltz R.L., Russanova V., Howard B.H., Nakatani Y.;
RT   "The transcriptional coactivators p300 and CBP are histone
RT   acetyltransferases.";
RL   Cell 87:953-959(1996).
RN   [8]
RP   INTERACTION WITH PCAF.
RX   PubMed=8684459; DOI=10.1038/382319a0;
RA   Yang X.-J., Ogryzko V.V., Nishikawa J., Howard B.H., Nakatani Y.;
RT   "A p300/CBP-associated factor that competes with the adenoviral
RT   oncoprotein E1A.";
RL   Nature 382:319-324(1996).
RN   [9]
RP   INTERACTION WITH HIF1A AND CREBBP.
RX   PubMed=8917528; DOI=10.1073/pnas.93.23.12969;
RA   Arany Z., Huang L.E., Eckner R., Bhattacharya S., Jiang C.,
RA   Goldberg M.A., Bunn H.F., Livingston D.M.;
RT   "An essential role for p300/CBP in the cellular response to hypoxia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:12969-12973(1996).
RN   [10]
RP   INTERACTION WITH HTLV-1 TAX.
RX   PubMed=9528808; DOI=10.1128/MCB.18.4.2392;
RA   Bex F., Yin M.-J., Burny A., Gaynor R.B.;
RT   "Differential transcriptional activation by human T-cell leukemia
RT   virus type 1 Tax mutants is mediated by distinct interactions with
RT   CREB binding protein and p300.";
RL   Mol. Cell. Biol. 18:2392-2405(1998).
RN   [11]
RP   INTERACTION WITH NR3C1.
RX   PubMed=9590696; DOI=10.1038/30032;
RA   Fryer C.J., Archer T.K.;
RT   "Chromatin remodelling by the glucocorticoid receptor requires the
RT   BRG1 complex.";
RL   Nature 393:88-91(1998).
RN   [12]
RP   INTERACTION WITH HIV-1 TAT.
RX   PubMed=10545121; DOI=10.1093/emboj/18.21.6106;
RA   Kiernan R.E., Vanhulle C., Schiltz L., Adam E., Xiao H., Maudoux F.,
RA   Calomme C., Burny A., Nakatani Y., Jeang K.-T., Benkirane M.,
RA   Van Lint C.;
RT   "HIV-1 tat transcriptional activity is regulated by acetylation.";
RL   EMBO J. 18:6106-6118(1999).
RN   [13]
RP   INTERACTION WITH CITED2 AND HIF1A, AND MUTAGENESIS OF 371-THR--LEU-376
RP   AND 413-VAL--LYS-418.
RX   PubMed=9887100; DOI=10.1101/gad.13.1.64;
RA   Bhattacharya S., Michels C.M., Leung M.K., Arany Z.P., Kung A.L.,
RA   Livingston D.M.;
RT   "Functional role of p35srj, a novel p300/CBP binding protein, during
RT   transactivation by HIF-1.";
RL   Genes Dev. 13:64-75(1999).
RN   [14]
RP   INTERACTION WITH RORA.
RX   PubMed=9862959; DOI=10.1093/nar/27.2.411;
RA   Lau P., Bailey P., Dowhan D.H., Muscat G.E.;
RT   "Exogenous expression of a dominant negative RORalpha1 vector in
RT   muscle cells impairs differentiation: RORalpha1 directly interacts
RT   with p300 and myoD.";
RL   Nucleic Acids Res. 27:411-420(1999).
RN   [15]
RP   INTERACTION WITH CITED1.
RX   PubMed=10722728; DOI=10.1074/jbc.275.12.8825;
RA   Yahata T., de Caestecker M.P., Lechleider R.J., Andriole S.,
RA   Roberts A.B., Isselbacher K.J., Shioda T.;
RT   "The MSG1 non-DNA-binding transactivator binds to the p300/CBP
RT   coactivators, enhancing their functional link to the Smad
RT   transcription factors.";
RL   J. Biol. Chem. 275:8825-8834(2000).
RN   [16]
RP   FUNCTION IN TRANSCRIPTIONAL REPRESSION.
RX   PubMed=10733570; DOI=10.1128/MCB.20.8.2676-2686.2000;
RA   Snowden A.W., Anderson L.A., Webster G.A., Perkins N.D.;
RT   "A novel transcriptional repression domain mediates p21(WAF1/CIP1)
RT   induction of p300 transactivation.";
RL   Mol. Cell. Biol. 20:2676-2686(2000).
RN   [17]
RP   ERRATUM.
RA   Snowden A.W., Anderson L.A., Webster G.A., Perkins N.D.;
RL   Mol. Cell. Biol. 20:5360-5360(2000).
RN   [18]
RP   INTERACTION WITH EID1.
RX   PubMed=11073989; DOI=10.1128/MCB.20.23.8889-8902.2000;
RA   Miyake S., Sellers W.R., Safran M., Li X., Zhao W., Grossman S.R.,
RA   Gan J., DeCaprio J.A., Adams P.D., Kaelin W.G. Jr.;
RT   "Cells degrade a novel inhibitor of differentiation with E1A-like
RT   properties upon exiting the cell cycle.";
RL   Mol. Cell. Biol. 20:8889-8902(2000).
RN   [19]
RP   INTERACTION WITH EID1.
RX   PubMed=11073990; DOI=10.1128/MCB.20.23.8903-8915.2000;
RA   MacLellan W.R., Xiao G., Abdellatif M., Schneider M.D.;
RT   "A novel Rb- and p300-binding protein inhibits transactivation by
RT   MyoD.";
RL   Mol. Cell. Biol. 20:8903-8915(2000).
RN   [20]
RP   INTERACTION WITH NCOA6.
RX   PubMed=10823961; DOI=10.1073/pnas.97.11.6212;
RA   Ko L., Cardona G.R., Chin W.W.;
RT   "Thyroid hormone receptor-binding protein, an LXXLL motif-containing
RT   protein, functions as a general coactivator.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:6212-6217(2000).
RN   [21]
RP   INTERACTION WITH HIV-1 TAT.
RX   PubMed=11080476; DOI=10.1006/viro.2000.0593;
RA   Deng L., de la Fuente C., Fu P., Wang L., Donnelly R., Wade J.D.,
RA   Lambert P., Li H., Lee C.-G., Kashanchi F.;
RT   "Acetylation of HIV-1 Tat by CBP/P300 increases transcription of
RT   integrated HIV-1 genome and enhances binding to core histones.";
RL   Virology 277:278-295(2000).
RN   [22]
RP   INTERACTION WITH ESR1.
RX   PubMed=11581164; DOI=10.1101/gad.906301;
RA   Yahata T., Shao W., Endoh H., Hur J., Coser K.R., Sun H., Ueda Y.,
RA   Kato S., Isselbacher K.J., Brown M., Shioda T.;
RT   "Selective coactivation of estrogen-dependent transcription by CITED1
RT   CBP/p300-binding protein.";
RL   Genes Dev. 15:2598-2612(2001).
RN   [23]
RP   PHOSPHORYLATION AT SER-89, MUTAGENESIS OF SER-89, AND INTERACTION WITH
RP   PPARG.
RX   PubMed=11518699; DOI=10.1074/jbc.C100316200;
RA   Yang W., Hong Y.H., Shen X.Q., Frankowski C., Camp H.S., Leff T.;
RT   "Regulation of transcription by AMP-activated protein kinase:
RT   phosphorylation of p300 blocks its interaction with nuclear
RT   receptors.";
RL   J. Biol. Chem. 276:38341-38344(2001).
RN   [24]
RP   INTERACTION WITH SRCAP.
RX   PubMed=11581372; DOI=10.1128/JVI.75.21.10033-10040.2001;
RA   Xu X., Chackalaparampil I., Monroy M.A., Cannella M.T., Pesek E.,
RA   Chrivia J., Yaciuk P.;
RT   "Adenovirus DNA binding protein interacts with the SNF2-related CBP
RT   activator protein (SrCap) and inhibits SrCap-mediated transcription.";
RL   J. Virol. 75:10033-10040(2001).
RN   [25]
RP   INTERACTION WITH HTLV-1 TAX.
RX   PubMed=11463834; DOI=10.1128/MCB.21.16.5520-5530.2001;
RA   Scoggin K.E.S., Ulloa A., Nyborg J.K.;
RT   "The oncoprotein Tax binds the SRC-1-interacting domain of CBP/p300 to
RT   mediate transcriptional activation.";
RL   Mol. Cell. Biol. 21:5520-5530(2001).
RN   [26]
RP   INTERACTION WITH HTLV-1 ACCESSORY PROTEIN P30II.
RX   PubMed=11559821; DOI=10.1128/JVI.75.20.9885-9895.2001;
RA   Zhang W., Nisbet J.W., Albrecht B., Ding W., Kashanchi F.,
RA   Bartoe J.T., Lairmore M.D.;
RT   "Human T-lymphotropic virus type 1 p30(II) regulates gene
RT   transcription by binding CREB binding protein/p300.";
RL   J. Virol. 75:9885-9895(2001).
RN   [27]
RP   INTERACTION WITH TRERF1.
RX   PubMed=11349124; DOI=10.1074/jbc.M100113200;
RA   Gizard F., Lavallee B., DeWitte F., Hum D.W.;
RT   "A novel zinc finger protein TReP-132 interacts with CBP/p300 to
RT   regulate human CYP11A1 gene expression.";
RL   J. Biol. Chem. 276:33881-33892(2001).
RN   [28]
RP   INTERACTION WITH PELP1.
RX   PubMed=11481323; DOI=10.1074/jbc.M103783200;
RA   Vadlamudi R.K., Wang R.-A., Mazumdar A., Kim Y.-S., Shin J., Sahin A.,
RA   Kumar R.;
RT   "Molecular cloning and characterization of PELP1, a novel human
RT   coregulator of estrogen receptor alpha.";
RL   J. Biol. Chem. 276:38272-38279(2001).
RN   [29]
RP   INTERACTION WITH DTX1.
RX   PubMed=11564735; DOI=10.1074/jbc.M105245200;
RA   Yamamoto N., Yamamoto S., Inagaki F., Kawaichi M., Fukamizu A.,
RA   Kishi N., Matsuno K., Nakamura K., Weinmaster G., Okano H.,
RA   Nakafuku M.;
RT   "Role of Deltex-1 as a transcriptional regulator downstream of the
RT   Notch receptor.";
RL   J. Biol. Chem. 276:45031-45040(2001).
RN   [30]
RP   FUNCTION, AND INTERACTION WITH FEN1.
RX   PubMed=11430825; DOI=10.1016/S1097-2765(01)00272-6;
RA   Hasan S., Stucki M., Hassa P.O., Imhof R., Gehrig P., Hunziker P.,
RA   Hubscher U., Hottiger M.O.;
RT   "Regulation of human flap endonuclease-1 activity by acetylation
RT   through the transcriptional coactivator p300.";
RL   Mol. Cell 7:1221-1231(2001).
RN   [31]
RP   INTERACTION WITH HADV5 E1A.
RX   PubMed=11433299; DOI=10.1038/35083062;
RA   Chan H.M., Krstic-Demonacos M., Smith L., Demonacos C.,
RA   La Thangue N.B.;
RT   "Acetylation control of the retinoblastoma tumour-suppressor
RT   protein.";
RL   Nat. Cell Biol. 3:667-674(2001).
RN   [32]
RP   INTERACTION WITH SPIB.
RX   PubMed=11864910;
RA   Yamamoto H., Kihara-Negishi F., Yamada T., Suzuki M., Nakano T.,
RA   Oikawa T.;
RT   "Interaction between the hematopoietic Ets transcription factor Spi-B
RT   and the coactivator CREB-binding protein associated with negative
RT   cross-talk with c-Myb.";
RL   Cell Growth Differ. 13:69-75(2002).
RN   [33]
RP   INTERACTION WITH CITED4.
RX   PubMed=11744733; DOI=10.1074/jbc.M110850200;
RA   Braganca J., Swingler T., Marques F.I.R., Jones T., Eloranta J.J.,
RA   Hurst H.C., Shioda T., Bhattacharya S.;
RT   "Human CREB-binding protein/p300-interacting transactivator with ED-
RT   rich tail (CITED) 4, a new member of the CITED family, functions as a
RT   co-activator for transcription factor AP-2.";
RL   J. Biol. Chem. 277:8559-8565(2002).
RN   [34]
RP   IDENTIFICATION IN A COMPLEX WITH CARM1 AND NCOA2.
RX   PubMed=11997499; DOI=10.1128/MCB.22.11.3621-3632.2002;
RA   Lee Y.-H., Koh S.S., Zhang X., Cheng X., Stallcup M.R.;
RT   "Synergy among nuclear receptor coactivators: selective requirement
RT   for protein methyltransferase and acetyltransferase activities.";
RL   Mol. Cell. Biol. 22:3621-3632(2002).
RN   [35]
RP   FUNCTION IN BCL6 ACETYLATION.
RX   PubMed=12402037; DOI=10.1038/ng1018;
RA   Bereshchenko O.R., Gu W., Dalla-Favera R.;
RT   "Acetylation inactivates the transcriptional repressor BCL6.";
RL   Nat. Genet. 32:606-613(2002).
RN   [36]
RP   INTERACTION WITH ING4 AND ING5.
RX   PubMed=12750254;
RA   Shiseki M., Nagashima M., Pedeux R.M., Kitahama-Shiseki M., Miura K.,
RA   Okamura S., Onogi H., Higashimoto Y., Appella E., Yokota J.,
RA   Harris C.C.;
RT   "p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity.";
RL   Cancer Res. 63:2373-2378(2003).
RN   [37]
RP   PHOSPHORYLATION, AND INTERACTION WITH TCF7L2 AND LEF1.
RX   PubMed=12446687; DOI=10.1074/jbc.M210081200;
RA   Hecht A., Stemmler M.P.;
RT   "Identification of a promoter-specific transcriptional activation
RT   domain at the C-terminus of the Wnt effector protein T-cell factor
RT   4.";
RL   J. Biol. Chem. 278:3776-3785(2003).
RN   [38]
RP   FUNCTION, INTERACTION WITH CITED2 AND TFAP2A, AND MUTAGENESIS OF
RP   ASP-1399.
RX   PubMed=12586840; DOI=10.1074/jbc.M208144200;
RA   Braganca J., Eloranta J.J., Bamforth S.D., Ibbitt J.C., Hurst H.C.,
RA   Bhattacharya S.;
RT   "Physical and functional interactions among AP-2 transcription
RT   factors, p300/CREB-binding protein, and CITED2.";
RL   J. Biol. Chem. 278:16021-16029(2003).
RN   [39]
RP   INTERACTION WITH SP3.
RX   PubMed=12837748; DOI=10.1074/jbc.M305961200;
RA   Ammanamanchi S., Freeman J.W., Brattain M.G.;
RT   "Acetylated SP3 is a transcriptional activator.";
RL   J. Biol. Chem. 278:35775-35780(2003).
RN   [40]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH ALX1, AND REGION.
RX   PubMed=12929931; DOI=10.1359/jbmr.2003.18.8.1419;
RA   Iioka T., Furukawa K., Yamaguchi A., Shindo H., Yamashita S.,
RA   Tsukazaki T.;
RT   "P300/CBP acts as a coactivator to cartilage homeoprotein-1 (Cart1),
RT   paired-like homeoprotein, through acetylation of the conserved lysine
RT   residue adjacent to the homeodomain.";
RL   J. Bone Miner. Res. 18:1419-1429(2003).
RN   [41]
RP   INTERACTION WITH SATB1.
RX   PubMed=14605447; DOI=10.1111/j.1348-0421.2003.tb03438.x;
RA   Fujii Y., Kumatori A., Nakamura M.;
RT   "SATB1 makes a complex with p300 and represses gp91(phox) promoter
RT   activity.";
RL   Microbiol. Immunol. 47:803-811(2003).
RN   [42]
RP   SUMOYLATION AT LYS-1020 AND LYS-1024, AND MUTAGENESIS OF LYS-1020 AND
RP   LYS-1024.
RX   PubMed=12718889; DOI=10.1016/S1097-2765(03)00141-2;
RA   Girdwood D., Bumpass D., Vaughan O.A., Thain A., Anderson L.A.,
RA   Snowden A.W., Garcia-Wilson E., Perkins N.D., Hay R.T.;
RT   "P300 transcriptional repression is mediated by SUMO modification.";
RL   Mol. Cell 11:1043-1054(2003).
RN   [43]
RP   INTERACTION WITH DDX5.
RX   PubMed=12527917; DOI=10.1038/sj.onc.1206067;
RA   Rossow K.L., Janknecht R.;
RT   "Synergism between p68 RNA helicase and the transcriptional
RT   coactivators CBP and p300.";
RL   Oncogene 22:151-156(2003).
RN   [44]
RP   INTERACTION WITH TP53, AND FUNCTION.
RX   PubMed=15186775; DOI=10.1016/j.cell.2004.05.009;
RA   An W., Kim J., Roeder R.G.;
RT   "Ordered cooperative functions of PRMT1, p300, and CARM1 in
RT   transcriptional activation by p53.";
RL   Cell 117:735-748(2004).
RN   [45]
RP   INTERACTION WITH SRY.
RX   PubMed=15297880; DOI=10.1038/sj.emboj.7600352;
RA   Thevenet L., Mejean C., Moniot B., Bonneaud N., Galeotti N.,
RA   Aldrian-Herrada G., Poulat F., Berta P., Benkirane M.,
RA   Boizet-Bonhoure B.;
RT   "Regulation of human SRY subcellular distribution by its
RT   acetylation/deacetylation.";
RL   EMBO J. 23:3336-3345(2004).
RN   [46]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH NPAS2;
RP   ARNTL/BMAL1 AND CLOCK.
RX   PubMed=14645221; DOI=10.1074/jbc.M311973200;
RA   Curtis A.M., Seo S.B., Westgate E.J., Rudic R.D., Smyth E.M.,
RA   Chakravarti D., FitzGerald G.A., McNamara P.;
RT   "Histone acetyltransferase-dependent chromatin remodeling and the
RT   vascular clock.";
RL   J. Biol. Chem. 279:7091-7097(2004).
RN   [47]
RP   INTERACTION WITH ELF3.
RX   PubMed=15075319; DOI=10.1074/jbc.M401356200;
RA   Wang H., Fang R., Cho J.-Y., Libermann T.A., Oettgen P.;
RT   "Positive and negative modulation of the transcriptional activity of
RT   the ETS factor ESE-1 through interaction with p300, CREB-binding
RT   protein, and Ku 70/86.";
RL   J. Biol. Chem. 279:25241-25250(2004).
RN   [48]
RP   INTERACTION WITH IRF1.
RX   PubMed=15509808; DOI=10.1128/MCB.24.22.10083-10098.2004;
RA   Dornan D., Eckert M., Wallace M., Shimizu H., Ramsay E., Hupp T.R.,
RA   Ball K.L.;
RT   "Interferon regulatory factor 1 binding to p300 stimulates DNA-
RT   dependent acetylation of p53.";
RL   Mol. Cell. Biol. 24:10083-10098(2004).
RN   [49]
RP   ACETYLATION AT LYS-1499; LYS-1549; LYS-1554; LYS-1558 AND LYS-1560.
RX   PubMed=15004546; DOI=10.1038/nsmb740;
RA   Thompson P.R., Wang D., Wang L., Fulco M., Pediconi N., Zhang D.,
RA   An W., Ge Q., Roeder R.G., Wong J., Levrero M., Sartorelli V.,
RA   Cotter R.J., Cole P.A.;
RT   "Regulation of the p300 HAT domain via a novel activation loop.";
RL   Nat. Struct. Mol. Biol. 11:308-315(2004).
RN   [50]
RP   INTERACTION WITH NEUROD1 AND TCF3.
RX   PubMed=14752053; DOI=10.1210/me.2003-0311;
RA   Kim J.Y., Chu K., Kim H.J., Seong H.A., Park K.C., Sanyal S.,
RA   Takeda J., Ha H., Shong M., Tsai M.J., Choi H.S.;
RT   "Orphan nuclear receptor small heterodimer partner, a novel
RT   corepressor for a basic helix-loop-helix transcription factor
RT   BETA2/neuroD.";
RL   Mol. Endocrinol. 18:776-790(2004).
RN   [51]
RP   INTERACTION WITH SS18L1/CREST.
RX   PubMed=14716005; DOI=10.1126/science.1089845;
RA   Aizawa H., Hu S.-C., Bobb K., Balakrishnan K., Ince G., Gurevich I.,
RA   Cowan M., Ghosh A.;
RT   "Dendrite development regulated by CREST, a calcium-regulated
RT   transcriptional activator.";
RL   Science 303:197-202(2004).
RN   [52]
RP   INVOLVEMENT IN RSTS2.
RX   PubMed=15706485; DOI=10.1086/429130;
RA   Roelfsema J.H., White S.J., Ariyuerek Y., Bartholdi D., Niedrist D.,
RA   Papadia F., Bacino C.A., den Dunnen J.T., van Ommen G.-J.B.,
RA   Breuning M.H., Hennekam R.C., Peters D.J.M.;
RT   "Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both
RT   the CBP and EP300 genes cause disease.";
RL   Am. J. Hum. Genet. 76:572-580(2005).
RN   [53]
RP   DEACETYLATION BY SIRT1, ACETYLATION AT LYS-1020 AND LYS-1024, AND
RP   MUTAGENESIS OF LYS-1020 AND LYS-1024.
RX   PubMed=15632193; DOI=10.1074/jbc.M408748200;
RA   Bouras T., Fu M., Sauve A.A., Wang F., Quong A.A., Perkins N.D.,
RA   Hay R.T., Gu W., Pestell R.G.;
RT   "SIRT1 deacetylation and repression of p300 involves lysine residues
RT   1020/1024 within the cell cycle regulatory domain 1.";
RL   J. Biol. Chem. 280:10264-10276(2005).
RN   [54]
RP   INTERACTION WITH FOXO1, FUNCTION, AND MUTAGENESIS OF ASP-1399.
RX   PubMed=15890677; DOI=10.1210/me.2004-0292;
RA   Perrot V., Rechler M.M.;
RT   "The coactivator p300 directly acetylates the forkhead transcription
RT   factor Foxo1 and stimulates Foxo1-induced transcription.";
RL   Mol. Endocrinol. 19:2283-2298(2005).
RN   [55]
RP   METHYLATION AT ARG-2142, CITRULLINATION AT ARG-2142, INTERACTION WITH
RP   NCOA2, AND MUTAGENESIS OF ARG-2056; ARG-2088 AND ARG-2142.
RX   PubMed=15731352; DOI=10.1073/pnas.0407159102;
RA   Lee Y.-H., Coonrod S.A., Kraus W.L., Jelinek M.A., Stallcup M.R.;
RT   "Regulation of coactivator complex assembly and function by protein
RT   arginine methylation and demethylimination.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:3611-3616(2005).
RN   [56]
RP   SUBCELLULAR LOCATION, INTERACTION WITH ROCK2, AND PHOSPHORYLATION AT
RP   SER-89.
RX   PubMed=16574662; DOI=10.1074/jbc.M510954200;
RA   Tanaka T., Nishimura D., Wu R.C., Amano M., Iso T., Kedes L.,
RA   Nishida H., Kaibuchi K., Hamamori Y.;
RT   "Nuclear Rho kinase, ROCK2, targets p300 acetyltransferase.";
RL   J. Biol. Chem. 281:15320-15329(2006).
RN   [57]
RP   INTERACTION WITH CITED1.
RX   PubMed=16864582; DOI=10.1074/jbc.M602631200;
RA   Shi G., Boyle S.C., Sparrow D.B., Dunwoodie S.L., Shioda T.,
RA   de Caestecker M.P.;
RT   "The transcriptional activity of CITED1 is regulated by
RT   phosphorylation in a cell cycle-dependent manner.";
RL   J. Biol. Chem. 281:27426-27435(2006).
RN   [58]
RP   ACETYLATION AT LYS-1336 AND LYS-1473, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=17065153; DOI=10.1074/jbc.M608813200;
RA   Karanam B., Jiang L., Wang L., Kelleher N.L., Cole P.A.;
RT   "Kinetic and mass spectrometric analysis of p300 histone
RT   acetyltransferase domain autoacetylation.";
RL   J. Biol. Chem. 281:40292-40301(2006).
RN   [59]
RP   FUNCTION IN ACETYLATION OF HDAC1.
RX   PubMed=16762839; DOI=10.1016/j.molcel.2006.04.019;
RA   Qiu Y., Zhao Y., Becker M., John S., Parekh B.S., Huang S.,
RA   Hendarwanto A., Martinez E.D., Chen Y., Lu H., Adkins N.L.,
RA   Stavreva D.A., Wiench M., Georgel P.T., Schiltz R.L., Hager G.L.;
RT   "HDAC1 acetylation is linked to progressive modulation of steroid
RT   receptor-induced gene transcription.";
RL   Mol. Cell 22:669-679(2006).
RN   [60]
RP   INTERACTION WITH SP1.
RX   PubMed=16478997; DOI=10.1128/MCB.26.5.1770-1785.2006;
RA   Hung J.J., Wang Y.T., Chang W.C.;
RT   "Sp1 deacetylation induced by phorbol ester recruits p300 to activate
RT   12(S)-lipoxygenase gene transcription.";
RL   Mol. Cell. Biol. 26:1770-1785(2006).
RN   [61]
RP   FUNCTION, AND INTERACTION WITH MTA1.
RX   PubMed=16617102; DOI=10.1073/pnas.0601989103;
RA   Gururaj A.E., Singh R.R., Rayala S.K., Holm C., den Hollander P.,
RA   Zhang H., Balasenthil S., Talukder A.H., Landberg G., Kumar R.;
RT   "MTA1, a transcriptional activator of breast cancer amplified sequence
RT   3.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:6670-6675(2006).
RN   [62]
RP   ERRATUM.
RA   Gururaj A.E., Singh R.R., Rayala S.K., Holm C., den Hollander P.,
RA   Zhang H., Balasenthil S., Talukder A.H., Landberg G., Kumar R.;
RL   Proc. Natl. Acad. Sci. U.S.A. 110:4147-4148(2013).
RN   [63]
RP   INTERACTION WITH DDIT3.
RX   PubMed=17872950; DOI=10.1074/jbc.M703735200;
RA   Ohoka N., Hattori T., Kitagawa M., Onozaki K., Hayashi H.;
RT   "Critical and functional regulation of CHOP (C/EBP homologous protein)
RT   through the N-terminal portion.";
RL   J. Biol. Chem. 282:35687-35694(2007).
RN   [64]
RP   INTERACTION WITH DDX17.
RX   PubMed=17226766; DOI=10.1002/jcb.21250;
RA   Shin S., Janknecht R.;
RT   "Concerted activation of the Mdm2 promoter by p72 RNA helicase and the
RT   coactivators p300 and P/CAF.";
RL   J. Cell. Biochem. 101:1252-1265(2007).
RN   [65]
RP   FUNCTION IN ACETYLATION OF SIRT2.
RX   PubMed=18722353; DOI=10.1016/j.bbrc.2008.08.042;
RA   Han Y., Jin Y.H., Kim Y.J., Kang B.Y., Choi H.J., Kim D.W., Yeo C.Y.,
RA   Lee K.Y.;
RT   "Acetylation of Sirt2 by p300 attenuates its deacetylase activity.";
RL   Biochem. Biophys. Res. Commun. 375:576-580(2008).
RN   [66]
RP   PHOSPHORYLATION BY HIPK2.
RX   PubMed=18695000; DOI=10.1182/blood-2008-01-134122;
RA   Wee H.-J., Voon D.C.-C., Bae S.-C., Ito Y.;
RT   "PEBP2-beta/CBF-beta-dependent phosphorylation of RUNX1 and p300 by
RT   HIPK2: implications for leukemogenesis.";
RL   Blood 112:3777-3787(2008).
RN   [67]
RP   FBXO3-MEDIATED DEGRADATION.
RX   PubMed=18809579; DOI=10.1128/MCB.00897-08;
RA   Shima Y., Shima T., Chiba T., Irimura T., Pandolfi P.P.,
RA   Kitabayashi I.;
RT   "PML activates transcription by protecting HIPK2 and p300 from
RT   SCFFbx3-mediated degradation.";
RL   Mol. Cell. Biol. 28:7126-7138(2008).
RN   [68]
RP   ACETYLATION AT LYS-418; LYS-423; LYS-1542; LYS-1546; LYS-1549;
RP   LYS-1699; LYS-1704 AND LYS-1707, DEACETYLATION BY SIRT2, AND FUNCTION
RP   IN TRANSCRIPTIONAL REGULATION.
RX   PubMed=18995842; DOI=10.1016/j.molcel.2008.09.018;
RA   Black J.C., Mosley A., Kitada T., Washburn M., Carey M.;
RT   "The SIRT2 deacetylase regulates autoacetylation of p300.";
RL   Mol. Cell 32:449-455(2008).
RN   [69]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [70]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [71]
RP   INTERACTION WITH SENP3, AND SUMOYLATION.
RX   PubMed=19680224; DOI=10.1038/emboj.2009.210;
RA   Huang C., Han Y., Wang Y., Sun X., Yan S., Yeh E.T.H., Chen Y.,
RA   Cang H., Li H., Shi G., Cheng J., Tang X., Yi J.;
RT   "SENP3 is responsible for HIF-1 transactivation under mild oxidative
RT   stress via p300 de-SUMOylation.";
RL   EMBO J. 28:2748-2762(2009).
RN   [72]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [73]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-636; LYS-977; LYS-1542;
RP   LYS-1546; LYS-1554; LYS-1555; LYS-1558; LYS-1560 AND LYS-1583, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [74]
RP   IDENTIFICATION IN COMPLEX WITH CCNT1; CDK9 AND GATA4.
RX   PubMed=20081228; DOI=10.1074/jbc.M109.070458;
RA   Sunagawa Y., Morimoto T., Takaya T., Kaichi S., Wada H., Kawamura T.,
RA   Fujita M., Shimatsu A., Kita T., Hasegawa K.;
RT   "Cyclin-dependent kinase-9 is a component of the p300/GATA4 complex
RT   required for phenylephrine-induced hypertrophy in cardiomyocytes.";
RL   J. Biol. Chem. 285:9556-9568(2010).
RN   [75]
RP   FUNCTION IN ACETYLATION OF MEF2D.
RX   PubMed=21030595; DOI=10.1074/jbc.M110.153270;
RA   Chini C.C., Escande C., Nin V., Chini E.N.;
RT   "HDAC3 is negatively regulated by the nuclear protein DBC1.";
RL   J. Biol. Chem. 285:40830-40837(2010).
RN   [76]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [77]
RP   FUNCTION IN ACETYLATION OF XBP1.
RX   PubMed=20955178; DOI=10.1042/BJ20101293;
RA   Wang F.M., Chen Y.J., Ouyang H.J.;
RT   "Regulation of unfolded protein response modulator XBP1s by
RT   acetylation and deacetylation.";
RL   Biochem. J. 433:245-252(2011).
RN   [78]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1038, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [79]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [80]
RP   INTERACTION WITH ALKBH4.
RX   PubMed=23145062; DOI=10.1371/journal.pone.0049045;
RA   Bjornstad L.G., Meza T.J., Otterlei M., Olafsrud S.M.,
RA   Meza-Zepeda L.A., Falnes P.O.;
RT   "Human ALKBH4 interacts with proteins associated with transcription.";
RL   PLoS ONE 7:E49045-E49045(2012).
RN   [81]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=23415232; DOI=10.1016/j.cell.2013.01.032;
RA   Tropberger P., Pott S., Keller C., Kamieniarz-Gdula K., Caron M.,
RA   Richter F., Li G., Mittler G., Liu E.T., Buhler M., Margueron R.,
RA   Schneider R.;
RT   "Regulation of transcription through acetylation of H3K122 on the
RT   lateral surface of the histone octamer.";
RL   Cell 152:859-872(2013).
RN   [82]
RP   FUNCTION AS ACETYLTRANSFERASE OF H3K27.
RX   PubMed=23911289; DOI=10.1016/j.celrep.2013.06.016;
RA   Hatzi K., Jiang Y., Huang C., Garrett-Bakelman F., Gearhart M.D.,
RA   Giannopoulou E.G., Zumbo P., Kirouac K., Bhaskara S., Polo J.M.,
RA   Kormaksson M., Mackerell A.D. Jr., Xue F., Mason C.E., Hiebert S.W.,
RA   Prive G.G., Cerchietti L., Bardwell V.J., Elemento O., Melnick A.;
RT   "A hybrid mechanism of action for BCL6 in B cells defined by formation
RT   of functionally distinct complexes at enhancers and promoters.";
RL   Cell Rep. 4:578-588(2013).
RN   [83]
RP   INTERACTION WITH KLF15.
RX   PubMed=23999430; DOI=10.1172/JCI68552;
RA   Lu Y., Zhang L., Liao X., Sangwung P., Prosdocimo D.A., Zhou G.,
RA   Votruba A.R., Brian L., Han Y.J., Gao H., Wang Y., Shimizu K.,
RA   Weinert-Stein K., Khrestian M., Simon D.I., Freedman N.J., Jain M.K.;
RT   "Kruppel-like factor 15 is critical for vascular inflammation.";
RL   J. Clin. Invest. 123:4232-4241(2013).
RN   [84]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1038 AND SER-1726, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [85]
RP   INTERACTION WITH HDAC4 AND HDAC5.
RX   PubMed=24413532; DOI=10.1158/0008-5472.CAN-13-2020;
RA   Kang H.J., Lee M.H., Kang H.L., Kim S.H., Ahn J.R., Na H., Na T.Y.,
RA   Kim Y.N., Seong J.K., Lee M.O.;
RT   "Differential regulation of estrogen receptor alpha expression in
RT   breast cancer cells by metastasis-associated protein 1.";
RL   Cancer Res. 74:1484-1494(2014).
RN   [86]
RP   INTERACTION WITH ZNF451, AND FUNCTION.
RX   PubMed=24324267; DOI=10.1074/jbc.M113.526905;
RA   Feng Y., Wu H., Xu Y., Zhang Z., Liu T., Lin X., Feng X.H.;
RT   "Zinc finger protein 451 is a novel Smad corepressor in transforming
RT   growth factor-beta signaling.";
RL   J. Biol. Chem. 289:2072-2083(2014).
RN   [87]
RP   INTERACTION WITH ZBTB48.
RX   PubMed=24382891; DOI=10.1074/jbc.M113.526855;
RA   Yoon J.H., Choi W.I., Jeon B.N., Koh D.I., Kim M.K., Kim M.H., Kim J.,
RA   Hur S.S., Kim K.S., Hur M.W.;
RT   "Human Kruppel-related 3 (HKR3) is a novel transcription activator of
RT   alternate reading frame (ARF) gene.";
RL   J. Biol. Chem. 289:4018-4031(2014).
RN   [88]
RP   ACETYLATION, DEACETYLATION BY SIRT2, AND INTERACTION WITH EP300.
RX   PubMed=24177535; DOI=10.1016/j.jmb.2013.10.027;
RA   Rack J.G., Vanlinden M.R., Lutter T., Aasland R., Ziegler M.;
RT   "Constitutive nuclear localization of an alternatively spliced
RT   sirtuin-2 isoform.";
RL   J. Mol. Biol. 426:1677-1691(2014).
RN   [89]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1038, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [90]
RP   INTERACTION WITH TRIP4.
RX   PubMed=25219498; DOI=10.1016/j.molcel.2014.08.007;
RA   Yoo H.M., Kang S.H., Kim J.Y., Lee J.E., Seong M.W., Lee S.W.,
RA   Ka S.H., Sou Y.S., Komatsu M., Tanaka K., Lee S.T., Noh D.Y.,
RA   Baek S.H., Jeon Y.J., Chung C.H.;
RT   "Modification of ASC1 by UFM1 is crucial for ERalpha transactivation
RT   and breast cancer development.";
RL   Mol. Cell 56:261-274(2014).
RN   [91]
RP   FUNCTION AS ACETYLTRANSFERASE OF PCNA, AND INTERACTION WITH PCNA.
RX   PubMed=24939902; DOI=10.1093/nar/gku533;
RA   Cazzalini O., Sommatis S., Tillhon M., Dutto I., Bachi A., Rapp A.,
RA   Nardo T., Scovassi A.I., Necchi D., Cardoso M.C., Stivala L.A.,
RA   Prosperi E.;
RT   "CBP and p300 acetylate PCNA to link its degradation with nucleotide
RT   excision repair synthesis.";
RL   Nucleic Acids Res. 42:8433-8448(2014).
RN   [92]
RP   INTERACTION WITH ZBTB49.
RX   PubMed=25245946; DOI=10.1093/nar/gku857;
RA   Jeon B.N., Kim M.K., Yoon J.H., Kim M.Y., An H., Noh H.J., Choi W.I.,
RA   Koh D.I., Hur M.W.;
RT   "Two ZNF509 (ZBTB49) isoforms induce cell-cycle arrest by activating
RT   transcription of p21/CDKN1A and RB upon exposure to genotoxic
RT   stress.";
RL   Nucleic Acids Res. 42:11447-11461(2014).
RN   [93]
RP   INTERACTION WITH HSF1.
RX   PubMed=27189267; DOI=10.1038/srep26294;
RA   Pan X.Y., Zhao W., Zeng X.Y., Lin J., Li M.M., Shen X.T., Liu S.W.;
RT   "Heat shock factor 1 mediates latent HIV reactivation.";
RL   Sci. Rep. 6:26294-26294(2016).
RN   [94]
RP   STRUCTURE BY NMR OF 302-418 IN COMPLEX WITH HIF1A PEPTIDE AND ZINC
RP   IONS.
RX   PubMed=11959990; DOI=10.1073/pnas.082117899;
RA   Freedman S.J., Sun Z.-Y.J., Poy F., Kung A.L., Livingston D.M.,
RA   Wagner G., Eck M.J.;
RT   "Structural basis for recruitment of CBP/p300 by hypoxia-inducible
RT   factor-1 alpha.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:5367-5372(2002).
RN   [95]
RP   STRUCTURE BY NMR OF 323-423 IN COMPLEX WITH 216-259 OF CITED2 AND ZINC
RP   IONS, INTERACTION WITH CITED2, AND MUTAGENESIS OF LEU-344 AND LEU-345.
RX   PubMed=12778114; DOI=10.1038/nsb936;
RA   Freedman S.J., Sun Z.Y., Kung A.L., France D.S., Wagner G., Eck M.J.;
RT   "Structural basis for negative regulation of hypoxia-inducible factor-
RT   1alpha by CITED2.";
RL   Nat. Struct. Biol. 10:504-512(2003).
RN   [96]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 1287-1666 IN COMPLEX WITH
RP   LYS-COA, AND MUTAGENESIS OF THR-1357; SER-1396; TYR-1397; GLU-1505;
RP   ASP-1625 AND ASP-1628.
RX   PubMed=18273021; DOI=10.1038/nature06546;
RA   Liu X., Wang L., Zhao K., Thompson P.R., Hwang Y., Marmorstein R.,
RA   Cole P.A.;
RT   "The structural basis of protein acetylation by the p300/CBP
RT   transcriptional coactivator.";
RL   Nature 451:846-850(2008).
RN   [97]
RP   STRUCTURE BY NMR OF 1723-1812, AND INTERACTION WITH TP53.
RX   PubMed=19217391; DOI=10.1016/j.str.2008.12.009;
RA   Feng H., Jenkins L.M.M., Durell S.R., Hayashi R., Mazur S.J.,
RA   Cherry S., Tropea J.E., Miller M., Wlodawer A., Appella E., Bai Y.;
RT   "Structural basis for p300 Taz2-p53 TAD1 binding and modulation by
RT   phosphorylation.";
RL   Structure 17:202-210(2009).
RN   [98]
RP   X-RAY CRYSTALLOGRAPHY (2.33 ANGSTROMS) OF 1040-1161.
RX   PubMed=22464331; DOI=10.1016/j.cell.2012.02.013;
RA   Filippakopoulos P., Picaud S., Mangos M., Keates T., Lambert J.P.,
RA   Barsyte-Lovejoy D., Felletar I., Volkmer R., Muller S., Pawson T.,
RA   Gingras A.C., Arrowsmith C.H., Knapp S.;
RT   "Histone recognition and large-scale structural analysis of the human
RT   bromodomain family.";
RL   Cell 149:214-231(2012).
RN   [99]
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 1043-1519 AND 1581-1666 OF
RP   MUTANT PHE-1467 IN COMPLEX WITH ZINC, CATALYTIC ACTIVITY, FUNCTION,
RP   AUTOACETYLATION, AND MUTAGENESIS OF PHE-1170; CYS-1204; GLU-1242;
RP   ASP-1399; TYR-1467 AND 1645-ARG-ARG-1646.
RX   PubMed=23934153; DOI=10.1038/nsmb.2642;
RA   Delvecchio M., Gaucher J., Aguilar-Gurrieri C., Ortega E., Panne D.;
RT   "Structure of the p300 catalytic core and implications for chromatin
RT   targeting and HAT regulation.";
RL   Nat. Struct. Mol. Biol. 20:1040-1046(2013).
RN   [100]
RP   X-RAY CRYSTALLOGRAPHY (1.94 ANGSTROMS) OF 1287-1664 OF MUTANT PHE-1467
RP   IN COMPLEX WITH ACETYL-COA AND COENZYME A.
RX   PubMed=24819397; DOI=10.1021/bi500380f;
RA   Maksimoska J., Segura-Pena D., Cole P.A., Marmorstein R.;
RT   "Structure of the p300 histone acetyltransferase bound to acetyl-
RT   coenzyme A and its analogues.";
RL   Biochemistry 53:3415-3422(2014).
RN   [101]
RP   VARIANTS PRO-827; GLY-1013; TYR-1650 AND GLN-2221, AND POSSIBLE
RP   INVOLVEMENT IN CANCER.
RX   PubMed=10700188; DOI=10.1038/73536;
RA   Gayther S.A., Batley S.J., Linger L., Bannister A., Thorpe K.,
RA   Chin S.-F., Daigo Y., Russell P., Wilson A., Sowter H.M.,
RA   Delhanty J.D.A., Ponder B.A.J., Kouzarides T., Caldas C.;
RT   "Mutations truncating the EP300 acetylase in human cancers.";
RL   Nat. Genet. 24:300-303(2000).
RN   [102]
RP   VARIANT ILE-1511.
RX   PubMed=24476420; DOI=10.1111/cge.12348;
RA   Negri G., Milani D., Colapietro P., Forzano F., Della Monica M.,
RA   Rusconi D., Consonni L., Caffi L.G., Finelli P., Scarano G.,
RA   Magnani C., Selicorni A., Spena S., Larizza L., Gervasini C.;
RT   "Clinical and molecular characterization of Rubinstein-Taybi syndrome
RT   patients carrying distinct novel mutations of the EP300 gene.";
RL   Clin. Genet. 87:148-154(2015).
CC   -!- FUNCTION: Functions as histone acetyltransferase and regulates
CC       transcription via chromatin remodeling. Acetylates all four core
CC       histones in nucleosomes. Histone acetylation gives an epigenetic
CC       tag for transcriptional activation. Mediates cAMP-gene regulation
CC       by binding specifically to phosphorylated CREB protein. Mediates
CC       acetylation of histone H3 at 'Lys-122' (H3K122ac), a modification
CC       that localizes at the surface of the histone octamer and
CC       stimulates transcription, possibly by promoting nucleosome
CC       instability. Mediates acetylation of histone H3 at 'Lys-27'
CC       (H3K27ac). Also functions as acetyltransferase for nonhistone
CC       targets. Acetylates 'Lys-131' of ALX1 and acts as its coactivator.
CC       Acetylates SIRT2 and is proposed to indirectly increase the
CC       transcriptional activity of TP53 through acetylation and
CC       subsequent attenuation of SIRT2 deacetylase function. Acetylates
CC       HDAC1 leading to its inactivation and modulation of transcription.
CC       Acts as a TFAP2A-mediated transcriptional coactivator in presence
CC       of CITED2. Plays a role as a coactivator of NEUROD1-dependent
CC       transcription of the secretin and p21 genes and controls terminal
CC       differentiation of cells in the intestinal epithelium. Promotes
CC       cardiac myocyte enlargement. Can also mediate transcriptional
CC       repression. Binds to and may be involved in the transforming
CC       capacity of the adenovirus E1A protein. In case of HIV-1
CC       infection, it is recruited by the viral protein Tat. Regulates
CC       Tat's transactivating activity and may help inducing chromatin
CC       remodeling of proviral genes. Acetylates FOXO1 and enhances its
CC       transcriptional activity. Acetylates BCL6 wich disrupts its
CC       ability to recruit histone deacetylases and hinders its
CC       transcriptional repressor activity. Participates in CLOCK or
CC       NPAS2-regulated rhythmic gene transcription; exhibits a circadian
CC       association with CLOCK or NPAS2, correlating with increase in
CC       PER1/2 mRNA and histone H3 acetylation on the PER1/2 promoter.
CC       Acetylates MTA1 at 'Lys-626' which is essential for its
CC       transcriptional coactivator activity (PubMed:10733570,
CC       PubMed:11430825, PubMed:11701890, PubMed:12402037,
CC       PubMed:12586840, PubMed:12929931, PubMed:14645221,
CC       PubMed:15186775, PubMed:15890677, PubMed:16617102,
CC       PubMed:16762839, PubMed:18722353, PubMed:18995842,
CC       PubMed:23415232, PubMed:23911289, PubMed:23934153,
CC       PubMed:8945521). Acetylates XBP1 isoform 2; acetylation increases
CC       protein stability of XBP1 isoform 2 and enhances its
CC       transcriptional activity (PubMed:20955178). Acetylates PCNA;
CC       acetylation promotes removal of chromatin-bound PCNA and its
CC       degradation during nucleotide excision repair (NER)
CC       (PubMed:24939902). Acetylates MEF2D. {ECO:0000269|PubMed:10733570,
CC       ECO:0000269|PubMed:11430825, ECO:0000269|PubMed:11701890,
CC       ECO:0000269|PubMed:12402037, ECO:0000269|PubMed:12586840,
CC       ECO:0000269|PubMed:12929931, ECO:0000269|PubMed:14645221,
CC       ECO:0000269|PubMed:15186775, ECO:0000269|PubMed:15890677,
CC       ECO:0000269|PubMed:16617102, ECO:0000269|PubMed:16762839,
CC       ECO:0000269|PubMed:18722353, ECO:0000269|PubMed:18995842,
CC       ECO:0000269|PubMed:21030595, ECO:0000269|PubMed:23415232,
CC       ECO:0000269|PubMed:23911289, ECO:0000269|PubMed:23934153,
CC       ECO:0000269|PubMed:24939902, ECO:0000269|PubMed:8945521,
CC       ECO:0000305|PubMed:20955178}.
CC   -!- CATALYTIC ACTIVITY: Acetyl-CoA + [protein]-L-lysine = CoA +
CC       [protein]-N(6)-acetyl-L-lysine. {ECO:0000269|PubMed:23415232,
CC       ECO:0000269|PubMed:23934153, ECO:0000269|PubMed:8945521}.
CC   -!- SUBUNIT: Interacts with phosphorylated CREB1. Interacts with
CC       HIF1A; the interaction is stimulated in response to hypoxia and
CC       inhibited by CITED2. Interacts (via N-terminus) with TFAP2A (via
CC       N-terminus); the interaction requires CITED2. Interacts (via CH1
CC       domain) with CITED2 (via C-terminus). Interacts with CITED1
CC       (unphosphorylated form preferentially and via C-terminus).
CC       Interacts with ESR1; the interaction is estrogen-dependent and
CC       enhanced by CITED1. Interacts with DTX1, EID1, ELF3, FEN1, LEF1,
CC       NCOA1, NCOA6, NR3C1, PCAF, PELP1, PRDM6, SP1, SP3, SPIB, SRY,
CC       TCF7L2, TP53, DDX5, DDX17, SATB1, SRCAP, TTC5, JMY and TRERF1. The
CC       TAZ-type 1 domain interacts with HIF1A. Probably part of a complex
CC       with HIF1A and CREBBP. Part of a complex containing CARM1 and
CC       NCOA2/GRIP1. Interacts with ING4 and this interaction may be
CC       indirect. Interacts with ING5. Interacts with the C-terminal
CC       region of CITED4. Non-sumoylated EP300 preferentially interacts
CC       with SENP3. Interacts with SS18L1/CREST. Interacts with ALX1 (via
CC       homeobox domain). Interacts with NEUROD1; the interaction is
CC       inhibited by NR0B2. Interacts with TCF3. Interacts (via CREB-
CC       binding domain) with MYOCD (via C-terminus). Binds to HIPK2.
CC       Interacts with ROCK2 and PPARG. Forms a complex made of CDK9,
CC       CCNT1/cyclin-T1, EP300 and GATA4 that stimulates hypertrophy in
CC       cardiomyocytes. Interacts with IRF1 and this interaction enhances
CC       acetylation of p53/TP53 and stimulation of its activity. Interacts
CC       with FOXO1; the interaction acetylates FOXO1 and enhances its
CC       transcriptional activity. Interacts with ALKBH4 and DDIT3/CHOP.
CC       Interacts with KLF15. Interacts with CEBPB and RORA. Interacts
CC       with HTLV-1 Tax and p30II. Interacts with and acetylates HIV-1
CC       Tat. Interacts with NPAS2, ARNTL/BMAL1 and CLOCK. Interacts with
CC       SIRT2 isoform 1, isoform 2 and isoform 5. Interacts with MTA1.
CC       Interacts with HDAC4 and HDAC5 in the presence of TFAP2C
CC       (PubMed:10545121, PubMed:10722728, PubMed:10823961,
CC       PubMed:11073989, PubMed:11073990, PubMed:11080476,
CC       PubMed:11349124, PubMed:11430825, PubMed:11463834,
CC       PubMed:11481323, PubMed:11518699, PubMed:11559821,
CC       PubMed:11564735, PubMed:11581164, PubMed:11581372,
CC       PubMed:11701890, PubMed:11744733, PubMed:11864910,
CC       PubMed:11959990, PubMed:11997499, PubMed:12446687,
CC       PubMed:12527917, PubMed:12586840, PubMed:12750254,
CC       PubMed:12778114, PubMed:12837748, PubMed:12929931,
CC       PubMed:14605447, PubMed:14645221, PubMed:14716005,
CC       PubMed:14752053, PubMed:15075319, PubMed:15186775,
CC       PubMed:15297880, PubMed:15509808, PubMed:15731352,
CC       PubMed:15890677, PubMed:16478997, PubMed:16574662,
CC       PubMed:16617102, PubMed:16864582, PubMed:17226766,
CC       PubMed:17872950, PubMed:18273021, PubMed:19217391,
CC       PubMed:19680224, PubMed:20081228, PubMed:23145062,
CC       PubMed:23999430, PubMed:24177535, PubMed:24413532, PubMed:8684459,
CC       PubMed:8917528, PubMed:9528808, PubMed:9590696, PubMed:9862959,
CC       PubMed:9887100). Interacts with TRIP4 (PubMed:25219498). Directly
CC       interacts with ZBTB49; this interaction leads to synergistic
CC       transactivation of CDKN1A (PubMed:25245946). Interacts with NR4A3
CC       (By similarity). Interacts with ZNF451 (PubMed:24324267).
CC       Interacts with human adenovirus 5 E1A protein; this interaction
CC       stimulates the acetylation of RB1 by recruiting EP300 and RB1 into
CC       a multimeric-protein complex (PubMed:11433299). Interacts with
CC       ATF5; EP300 is required for ATF5 and CEBPB interaction and DNA
CC       binding (By similarity). Interacts with HSF1 (PubMed:27189267).
CC       Interacts with ZBTB48/TZAP (PubMed:24382891).
CC       {ECO:0000250|UniProtKB:B2RWS6, ECO:0000269|PubMed:10545121,
CC       ECO:0000269|PubMed:10722728, ECO:0000269|PubMed:10823961,
CC       ECO:0000269|PubMed:11073989, ECO:0000269|PubMed:11073990,
CC       ECO:0000269|PubMed:11080476, ECO:0000269|PubMed:11349124,
CC       ECO:0000269|PubMed:11430825, ECO:0000269|PubMed:11433299,
CC       ECO:0000269|PubMed:11463834, ECO:0000269|PubMed:11481323,
CC       ECO:0000269|PubMed:11518699, ECO:0000269|PubMed:11559821,
CC       ECO:0000269|PubMed:11564735, ECO:0000269|PubMed:11581164,
CC       ECO:0000269|PubMed:11581372, ECO:0000269|PubMed:11701890,
CC       ECO:0000269|PubMed:11744733, ECO:0000269|PubMed:11864910,
CC       ECO:0000269|PubMed:11959990, ECO:0000269|PubMed:11997499,
CC       ECO:0000269|PubMed:12446687, ECO:0000269|PubMed:12527917,
CC       ECO:0000269|PubMed:12586840, ECO:0000269|PubMed:12750254,
CC       ECO:0000269|PubMed:12778114, ECO:0000269|PubMed:12837748,
CC       ECO:0000269|PubMed:12929931, ECO:0000269|PubMed:14605447,
CC       ECO:0000269|PubMed:14645221, ECO:0000269|PubMed:14716005,
CC       ECO:0000269|PubMed:14752053, ECO:0000269|PubMed:15075319,
CC       ECO:0000269|PubMed:15186775, ECO:0000269|PubMed:15297880,
CC       ECO:0000269|PubMed:15509808, ECO:0000269|PubMed:15731352,
CC       ECO:0000269|PubMed:15890677, ECO:0000269|PubMed:16478997,
CC       ECO:0000269|PubMed:16574662, ECO:0000269|PubMed:16617102,
CC       ECO:0000269|PubMed:16864582, ECO:0000269|PubMed:17226766,
CC       ECO:0000269|PubMed:17872950, ECO:0000269|PubMed:18273021,
CC       ECO:0000269|PubMed:19217391, ECO:0000269|PubMed:19680224,
CC       ECO:0000269|PubMed:20081228, ECO:0000269|PubMed:23145062,
CC       ECO:0000269|PubMed:23999430, ECO:0000269|PubMed:24177535,
CC       ECO:0000269|PubMed:24382891, ECO:0000269|PubMed:24413532,
CC       ECO:0000269|PubMed:25219498, ECO:0000269|PubMed:25245946,
CC       ECO:0000269|PubMed:27189267, ECO:0000269|PubMed:8684459,
CC       ECO:0000269|PubMed:8917528, ECO:0000269|PubMed:9528808,
CC       ECO:0000269|PubMed:9590696, ECO:0000269|PubMed:9862959,
CC       ECO:0000269|PubMed:9887100}.
CC   -!- INTERACTION:
CC       P03070:- (xeno); NbExp=2; IntAct=EBI-447295, EBI-617698;
CC       P03255:- (xeno); NbExp=3; IntAct=EBI-447295, EBI-2603114;
CC       P03255-2:- (xeno); NbExp=3; IntAct=EBI-447295, EBI-6859460;
CC       P03259:- (xeno); NbExp=3; IntAct=EBI-447295, EBI-6947456;
CC       P27695:APEX1; NbExp=8; IntAct=EBI-447295, EBI-1048805;
CC       Q9UBL3:ASH2L; NbExp=5; IntAct=EBI-447295, EBI-540797;
CC       K4P3M7:BICP0 (xeno); NbExp=4; IntAct=EBI-447295, EBI-11296047;
CC       Q9NPI1:BRD7; NbExp=3; IntAct=EBI-447295, EBI-711221;
CC       P24941:CDK2; NbExp=5; IntAct=EBI-447295, EBI-375096;
CC       Q99967:CITED2; NbExp=3; IntAct=EBI-447295, EBI-937732;
CC       P61201:COPS2; NbExp=2; IntAct=EBI-447295, EBI-1050386;
CC       P16220:CREB1; NbExp=2; IntAct=EBI-447295, EBI-711855;
CC       Q01147:Creb1 (xeno); NbExp=2; IntAct=EBI-447295, EBI-2291098;
CC       P17844:DDX5; NbExp=4; IntAct=EBI-447295, EBI-351962;
CC       P03122:E2 (xeno); NbExp=3; IntAct=EBI-447295, EBI-7028618;
CC       P06422:E2 (xeno); NbExp=7; IntAct=EBI-447295, EBI-7136851;
CC       P06790:E2 (xeno); NbExp=6; IntAct=EBI-447295, EBI-7010629;
CC       P03372:ESR1; NbExp=2; IntAct=EBI-447295, EBI-78473;
CC       Q00403:GTF2B; NbExp=2; IntAct=EBI-447295, EBI-389564;
CC       Q16665:HIF1A; NbExp=16; IntAct=EBI-447295, EBI-447269;
CC       Q61221:Hif1a (xeno); NbExp=2; IntAct=EBI-447295, EBI-298954;
CC       Q9H2X6:HIPK2; NbExp=4; IntAct=EBI-447295, EBI-348345;
CC       Q9QXM1:Jmy (xeno); NbExp=16; IntAct=EBI-447295, EBI-866001;
CC       Q92831:KAT2B; NbExp=2; IntAct=EBI-447295, EBI-477430;
CC       P55209:NAP1L1; NbExp=3; IntAct=EBI-447295, EBI-356392;
CC       O60934:NBN; NbExp=5; IntAct=EBI-447295, EBI-494844;
CC       Q9Y6Q9:NCOA3; NbExp=2; IntAct=EBI-447295, EBI-81196;
CC       P20265:POU3F2; NbExp=3; IntAct=EBI-447295, EBI-1167176;
CC       Q96KQ4:PPP1R13B; NbExp=2; IntAct=EBI-447295, EBI-1105153;
CC       Q8WUF5:PPP1R13L; NbExp=2; IntAct=EBI-447295, EBI-5550163;
CC       Q13761:RUNX3; NbExp=7; IntAct=EBI-447295, EBI-925990;
CC       Q96EB6:SIRT1; NbExp=2; IntAct=EBI-447295, EBI-1802965;
CC       Q13309:SKP2; NbExp=3; IntAct=EBI-447295, EBI-456291;
CC       O95863:SNAI1; NbExp=3; IntAct=EBI-447295, EBI-1045459;
CC       P42226:STAT6; NbExp=2; IntAct=EBI-447295, EBI-1186478;
CC       P04608:tat (xeno); NbExp=3; IntAct=EBI-447295, EBI-6164389;
CC       P05549:TFAP2A; NbExp=7; IntAct=EBI-447295, EBI-347351;
CC       P04637:TP53; NbExp=10; IntAct=EBI-447295, EBI-366083;
CC       Q13625:TP53BP2; NbExp=2; IntAct=EBI-447295, EBI-77642;
CC       P11473:VDR; NbExp=3; IntAct=EBI-447295, EBI-286357;
CC       P67809:YBX1; NbExp=2; IntAct=EBI-447295, EBI-354065;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=In the presence of
CC       ALX1 relocalizes from the cytoplasm to the nucleus. Colocalizes
CC       with ROCK2 in the nucleus.
CC   -!- DOMAIN: The CRD1 domain (cell cycle regulatory domain 1) mediates
CC       transcriptional repression of a subset of p300 responsive genes;
CC       it can be de-repressed by CDKN1A/p21WAF1 at least at some
CC       promoters. It conatins sumoylation and acetylation sites and the
CC       same lysine residues may be targeted for the respective
CC       modifications. It is proposed that deacetylation by SIRT1 allows
CC       sumoylation leading to suppressed activity.
CC   -!- PTM: Acetylated on Lys at up to 17 positions by intermolecular
CC       autocatalysis. Deacetylated in the transcriptional repression
CC       domain (CRD1) by SIRT1, preferentially at Lys-1020. Deacetylated
CC       by SIRT2, preferentially at Lys-418, Lys-423, Lys-1542, Lys-1546,
CC       Lys-1549, Lys-1699, Lys-1704 and Lys-1707.
CC       {ECO:0000269|PubMed:15004546, ECO:0000269|PubMed:15632193,
CC       ECO:0000269|PubMed:17065153, ECO:0000269|PubMed:18995842,
CC       ECO:0000269|PubMed:23934153, ECO:0000269|PubMed:24177535}.
CC   -!- PTM: Citrullinated at Arg-2142 by PADI4, which impairs methylation
CC       by CARM1 and promotes interaction with NCOA2/GRIP1.
CC       {ECO:0000269|PubMed:11701890, ECO:0000269|PubMed:15731352}.
CC   -!- PTM: Methylated at Arg-580 and Arg-604 in the KIX domain by CARM1,
CC       which blocks association with CREB, inhibits CREB signaling and
CC       activates apoptotic response. Also methylated at Arg-2142 by
CC       CARM1, which impairs interaction with NCOA2/GRIP1.
CC       {ECO:0000269|PubMed:11701890, ECO:0000269|PubMed:15731352}.
CC   -!- PTM: Sumoylated; sumoylation in the transcriptional repression
CC       domain (CRD1) mediates transcriptional repression. Desumoylated by
CC       SENP3 through the removal of SUMO2 and SUMO3.
CC       {ECO:0000269|PubMed:12718889, ECO:0000269|PubMed:19680224}.
CC   -!- PTM: Probable target of ubiquitination by FBXO3, leading to rapid
CC       proteasome-dependent degradation.
CC   -!- PTM: Phosphorylated by HIPK2 in a RUNX1-dependent manner. This
CC       phosphorylation that activates EP300 happens when RUNX1 is
CC       associated with DNA and CBFB. Phosphorylated by ROCK2 and this
CC       enhances its activity. Phosphorylation at Ser-89 by AMPK reduces
CC       interaction with nuclear receptors, such as PPARG.
CC       {ECO:0000269|PubMed:11518699, ECO:0000269|PubMed:12446687,
CC       ECO:0000269|PubMed:16574662, ECO:0000269|PubMed:18695000}.
CC   -!- DISEASE: Note=Defects in EP300 may play a role in epithelial
CC       cancer.
CC   -!- DISEASE: Note=Chromosomal aberrations involving EP300 may be a
CC       cause of acute myeloid leukemias. Translocation t(8;22)(p11;q13)
CC       with KAT6A.
CC   -!- DISEASE: Rubinstein-Taybi syndrome 2 (RSTS2) [MIM:613684]: A
CC       disorder characterized by craniofacial abnormalities, postnatal
CC       growth deficiency, broad thumbs, broad big toes, mental
CC       retardation and a propensity for development of malignancies. Some
CC       individuals with RSTS2 have less severe mental impairment, more
CC       severe microcephaly, and a greater degree of changes in facial
CC       bone structure than RSTS1 patients. {ECO:0000269|PubMed:15706485}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/P300ID97.html";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=P300/CBP entry;
CC       URL="https://en.wikipedia.org/wiki/P300/CBP";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U01877; AAA18639.1; -; mRNA.
DR   EMBL; AL080243; CAH70384.1; -; Genomic_DNA.
DR   EMBL; AL035658; CAH70384.1; JOINED; Genomic_DNA.
DR   EMBL; AL096765; CAH70384.1; JOINED; Genomic_DNA.
DR   EMBL; AL096765; CAH73688.1; -; Genomic_DNA.
DR   EMBL; AL035658; CAH73688.1; JOINED; Genomic_DNA.
DR   EMBL; AL080243; CAH73688.1; JOINED; Genomic_DNA.
DR   EMBL; AL035658; CAI23037.1; -; Genomic_DNA.
DR   EMBL; AL080243; CAI23037.1; JOINED; Genomic_DNA.
DR   EMBL; AL096765; CAI23037.1; JOINED; Genomic_DNA.
DR   EMBL; CH471095; EAW60408.1; -; Genomic_DNA.
DR   CCDS; CCDS14010.1; -.
DR   PIR; A54277; A54277.
DR   RefSeq; NP_001420.2; NM_001429.3.
DR   UniGene; Hs.517517; -.
DR   UniGene; Hs.655211; -.
DR   PDB; 1L3E; NMR; -; B=323-423.
DR   PDB; 1P4Q; NMR; -; B=323-423.
DR   PDB; 2K8F; NMR; -; A=1723-1812.
DR   PDB; 2MH0; NMR; -; B=1723-1812.
DR   PDB; 2MZD; NMR; -; A=1723-1812.
DR   PDB; 3BIY; X-ray; 1.70 A; A=1287-1666.
DR   PDB; 3I3J; X-ray; 2.33 A; A/B/C/D/E/F/G/H/I/J/K/L=1040-1161.
DR   PDB; 3IO2; X-ray; 2.50 A; A=1723-1836.
DR   PDB; 3P57; X-ray; 2.19 A; P=1726-1835.
DR   PDB; 3T92; X-ray; 1.50 A; A=1723-1818.
DR   PDB; 4BHW; X-ray; 2.80 A; A/B=1043-1519, A/B=1581-1666.
DR   PDB; 4PZR; X-ray; 2.10 A; A=1287-1664.
DR   PDB; 4PZS; X-ray; 1.94 A; A=1287-1664.
DR   PDB; 4PZT; X-ray; 2.80 A; A=1287-1664.
DR   PDB; 5BT3; X-ray; 1.05 A; A=1048-1161.
DR   PDB; 5LKT; X-ray; 2.04 A; A=1043-1519, A=1581-1666.
DR   PDB; 5LKU; X-ray; 3.50 A; A=1043-1519, A=1581-1666.
DR   PDB; 5LKX; X-ray; 2.52 A; A=1043-1519, A=1581-1666.
DR   PDB; 5LKZ; X-ray; 2.50 A; A=1043-1519, A=1581-1666.
DR   PDBsum; 1L3E; -.
DR   PDBsum; 1P4Q; -.
DR   PDBsum; 2K8F; -.
DR   PDBsum; 2MH0; -.
DR   PDBsum; 2MZD; -.
DR   PDBsum; 3BIY; -.
DR   PDBsum; 3I3J; -.
DR   PDBsum; 3IO2; -.
DR   PDBsum; 3P57; -.
DR   PDBsum; 3T92; -.
DR   PDBsum; 4BHW; -.
DR   PDBsum; 4PZR; -.
DR   PDBsum; 4PZS; -.
DR   PDBsum; 4PZT; -.
DR   PDBsum; 5BT3; -.
DR   PDBsum; 5LKT; -.
DR   PDBsum; 5LKU; -.
DR   PDBsum; 5LKX; -.
DR   PDBsum; 5LKZ; -.
DR   DisProt; DP00633; -.
DR   ProteinModelPortal; Q09472; -.
DR   SMR; Q09472; -.
DR   BioGrid; 108347; 488.
DR   DIP; DIP-257N; -.
DR   IntAct; Q09472; 187.
DR   MINT; MINT-104535; -.
DR   STRING; 9606.ENSP00000263253; -.
DR   BindingDB; Q09472; -.
DR   ChEMBL; CHEMBL3784; -.
DR   GuidetoPHARMACOLOGY; 2735; -.
DR   iPTMnet; Q09472; -.
DR   PhosphoSitePlus; Q09472; -.
DR   BioMuta; EP300; -.
DR   DMDM; 223590203; -.
DR   EPD; Q09472; -.
DR   MaxQB; Q09472; -.
DR   PaxDb; Q09472; -.
DR   PeptideAtlas; Q09472; -.
DR   PRIDE; Q09472; -.
DR   Ensembl; ENST00000263253; ENSP00000263253; ENSG00000100393.
DR   GeneID; 2033; -.
DR   KEGG; hsa:2033; -.
DR   UCSC; uc003azl.5; human.
DR   CTD; 2033; -.
DR   DisGeNET; 2033; -.
DR   GeneCards; EP300; -.
DR   GeneCards; MIR1281; -.
DR   GeneReviews; EP300; -.
DR   H-InvDB; HIX0203186; -.
DR   HGNC; HGNC:3373; EP300.
DR   HPA; CAB000146; -.
DR   HPA; HPA003128; -.
DR   HPA; HPA004112; -.
DR   MalaCards; EP300; -.
DR   MIM; 602700; gene.
DR   MIM; 613684; phenotype.
DR   neXtProt; NX_Q09472; -.
DR   OpenTargets; ENSG00000100393; -.
DR   Orphanet; 353284; Rubinstein-Taybi syndrome due to EP300 haploinsufficiency.
DR   PharmGKB; PA27807; -.
DR   eggNOG; KOG1778; Eukaryota.
DR   eggNOG; COG5076; LUCA.
DR   GeneTree; ENSGT00760000119206; -.
DR   HOGENOM; HOG000111353; -.
DR   HOVERGEN; HBG000185; -.
DR   InParanoid; Q09472; -.
DR   KO; K04498; -.
DR   OMA; PTMIRGS; -.
DR   OrthoDB; EOG091G0L04; -.
DR   PhylomeDB; Q09472; -.
DR   TreeFam; TF101097; -.
DR   BRENDA; 2.3.1.48; 2681.
DR   Reactome; R-HSA-1234158; Regulation of gene expression by Hypoxia-inducible Factor.
DR   Reactome; R-HSA-1368082; RORA activates gene expression.
DR   Reactome; R-HSA-1368108; BMAL1:CLOCK,NPAS2 activates circadian gene expression.
DR   Reactome; R-HSA-156711; Polo-like kinase mediated events.
DR   Reactome; R-HSA-1912408; Pre-NOTCH Transcription and Translation.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-201722; Formation of the beta-catenin:TCF transactivating complex.
DR   Reactome; R-HSA-2122947; NOTCH1 Intracellular Domain Regulates Transcription.
DR   Reactome; R-HSA-2197563; NOTCH2 intracellular domain regulates transcription.
DR   Reactome; R-HSA-2644606; Constitutive Signaling by NOTCH1 PEST Domain Mutants.
DR   Reactome; R-HSA-2894862; Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants.
DR   Reactome; R-HSA-3134973; LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production.
DR   Reactome; R-HSA-3214847; HATs acetylate histones.
DR   Reactome; R-HSA-3371568; Attenuation phase.
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   Reactome; R-HSA-400253; Circadian Clock.
DR   Reactome; R-HSA-5250924; B-WICH complex positively regulates rRNA expression.
DR   Reactome; R-HSA-5617472; Activation of anterior HOX genes in hindbrain development during early embryogenesis.
DR   Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling.
DR   Reactome; R-HSA-5689901; Metalloprotease DUBs.
DR   Reactome; R-HSA-6781823; Formation of TC-NER Pre-Incision Complex.
DR   Reactome; R-HSA-6781827; Transcription-Coupled Nucleotide Excision Repair (TC-NER).
DR   Reactome; R-HSA-6782135; Dual incision in TC-NER.
DR   Reactome; R-HSA-6782210; Gap-filling DNA repair synthesis and ligation in TC-NER.
DR   Reactome; R-HSA-6804114; TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest.
DR   Reactome; R-HSA-6804758; Regulation of TP53 Activity through Acetylation.
DR   Reactome; R-HSA-6804760; Regulation of TP53 Activity through Methylation.
DR   Reactome; R-HSA-6811555; PI5P Regulates TP53 Acetylation.
DR   Reactome; R-HSA-8866907; Activation of the TFAP2 (AP-2) family of transcription factors.
DR   Reactome; R-HSA-918233; TRAF3-dependent IRF activation pathway.
DR   Reactome; R-HSA-933541; TRAF6 mediated IRF7 activation.
DR   Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production.
DR   SignaLink; Q09472; -.
DR   SIGNOR; Q09472; -.
DR   ChiTaRS; EP300; human.
DR   EvolutionaryTrace; Q09472; -.
DR   GeneWiki; EP300; -.
DR   GenomeRNAi; 2033; -.
DR   PRO; PR:Q09472; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   Bgee; ENSG00000100393; -.
DR   CleanEx; HS_EP300; -.
DR   ExpressionAtlas; Q09472; baseline and differential.
DR   Genevisible; Q09472; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0000123; C:histone acetyltransferase complex; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005667; C:transcription factor complex; IEA:Ensembl.
DR   GO; GO:0016407; F:acetyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0033613; F:activating transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0050681; F:androgen receptor binding; IPI:BHF-UCL.
DR   GO; GO:0008013; F:beta-catenin binding; IPI:BHF-UCL.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0031490; F:chromatin DNA binding; IEA:Ensembl.
DR   GO; GO:0001047; F:core promoter binding; IDA:UniProtKB.
DR   GO; GO:0003684; F:damaged DNA binding; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0004402; F:histone acetyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0004468; F:lysine N-acetyltransferase activity, acting on acetyl phosphate as donor; IDA:UniProtKB.
DR   GO; GO:0035257; F:nuclear hormone receptor binding; IPI:UniProtKB.
DR   GO; GO:0002039; F:p53 binding; IEA:Ensembl.
DR   GO; GO:0034212; F:peptide N-acetyltransferase activity; TAS:Reactome.
DR   GO; GO:0061733; F:peptide-lysine-N-acetyltransferase activity; TAS:Reactome.
DR   GO; GO:0097157; F:pre-mRNA intronic binding; IEA:Ensembl.
DR   GO; GO:0008022; F:protein C-terminus binding; IDA:MGI.
DR   GO; GO:0001102; F:RNA polymerase II activating transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0000979; F:RNA polymerase II core promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0001228; F:transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding; IEA:Ensembl.
DR   GO; GO:0016746; F:transferase activity, transferring acyl groups; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0009887; P:animal organ morphogenesis; IEA:Ensembl.
DR   GO; GO:0006915; P:apoptotic process; IMP:UniProtKB.
DR   GO; GO:0030183; P:B cell differentiation; IEA:Ensembl.
DR   GO; GO:1904837; P:beta-catenin-TCF complex assembly; TAS:Reactome.
DR   GO; GO:0034644; P:cellular response to UV; IDA:UniProtKB.
DR   GO; GO:0007623; P:circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0006977; P:DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; TAS:Reactome.
DR   GO; GO:0045444; P:fat cell differentiation; ISS:UniProtKB.
DR   GO; GO:0007507; P:heart development; IEA:Ensembl.
DR   GO; GO:0043969; P:histone H2B acetylation; IDA:UniProtKB.
DR   GO; GO:0043967; P:histone H4 acetylation; IMP:UniProtKB.
DR   GO; GO:0018393; P:internal peptidyl-lysine acetylation; IDA:UniProtKB.
DR   GO; GO:0006475; P:internal protein amino acid acetylation; IDA:UniProtKB.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IDA:UniProtKB.
DR   GO; GO:0030324; P:lung development; IEA:Ensembl.
DR   GO; GO:0010742; P:macrophage derived foam cell differentiation; IDA:UniProtKB.
DR   GO; GO:0035855; P:megakaryocyte development; IEA:Ensembl.
DR   GO; GO:0018076; P:N-terminal peptidyl-lysine acetylation; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0007399; P:nervous system development; TAS:ProtInc.
DR   GO; GO:0007219; P:Notch signaling pathway; TAS:Reactome.
DR   GO; GO:0030220; P:platelet formation; IEA:Ensembl.
DR   GO; GO:0043923; P:positive regulation by host of viral transcription; IDA:BHF-UCL.
DR   GO; GO:0045815; P:positive regulation of gene expression, epigenetic; TAS:Reactome.
DR   GO; GO:0032092; P:positive regulation of protein binding; IEA:Ensembl.
DR   GO; GO:0051091; P:positive regulation of sequence-specific DNA binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0006990; P:positive regulation of transcription from RNA polymerase II promoter involved in unfolded protein response; ISS:UniProtKB.
DR   GO; GO:0032481; P:positive regulation of type I interferon production; TAS:Reactome.
DR   GO; GO:0006473; P:protein acetylation; IDA:UniProtKB.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0050821; P:protein stabilization; ISS:UniProtKB.
DR   GO; GO:0060765; P:regulation of androgen receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0010506; P:regulation of autophagy; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0051726; P:regulation of cell cycle; TAS:Reactome.
DR   GO; GO:1900034; P:regulation of cellular response to heat; TAS:Reactome.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0061418; P:regulation of transcription from RNA polymerase II promoter in response to hypoxia; TAS:Reactome.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0090043; P:regulation of tubulin deacetylation; IDA:UniProtKB.
DR   GO; GO:0043627; P:response to estrogen; IDA:UniProtKB.
DR   GO; GO:0001666; P:response to hypoxia; IDA:UniProtKB.
DR   GO; GO:0007519; P:skeletal muscle tissue development; IEA:Ensembl.
DR   GO; GO:0001756; P:somitogenesis; IEA:Ensembl.
DR   GO; GO:0002223; P:stimulatory C-type lectin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006283; P:transcription-coupled nucleotide-excision repair; TAS:Reactome.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   CDD; cd15802; RING_CBP-p300; 1.
DR   Gene3D; 1.10.1630.10; -; 1.
DR   Gene3D; 1.20.1020.10; -; 3.
DR   Gene3D; 1.20.920.10; -; 1.
DR   InterPro; IPR001487; Bromodomain.
DR   InterPro; IPR018359; Bromodomain_CS.
DR   InterPro; IPR031162; CBP_P300_HAT.
DR   InterPro; IPR013178; Histone_AcTrfase_Rtt109/CBP.
DR   InterPro; IPR003101; KIX_dom.
DR   InterPro; IPR009110; Nuc_rcpt_coact.
DR   InterPro; IPR014744; Nuc_rcpt_coact_CREBbp.
DR   InterPro; IPR010303; RING_CBP-p300.
DR   InterPro; IPR000197; Znf_TAZ.
DR   InterPro; IPR000433; Znf_ZZ.
DR   Pfam; PF00439; Bromodomain; 1.
DR   Pfam; PF09030; Creb_binding; 1.
DR   Pfam; PF06001; DUF902; 1.
DR   Pfam; PF08214; HAT_KAT11; 1.
DR   Pfam; PF02172; KIX; 1.
DR   Pfam; PF02135; zf-TAZ; 2.
DR   Pfam; PF00569; ZZ; 1.
DR   PRINTS; PR00503; BROMODOMAIN.
DR   SMART; SM00297; BROMO; 1.
DR   SMART; SM01250; KAT11; 1.
DR   SMART; SM00551; ZnF_TAZ; 2.
DR   SMART; SM00291; ZnF_ZZ; 1.
DR   SUPFAM; SSF47040; SSF47040; 1.
DR   SUPFAM; SSF47370; SSF47370; 1.
DR   SUPFAM; SSF57933; SSF57933; 2.
DR   SUPFAM; SSF69125; SSF69125; 1.
DR   PROSITE; PS00633; BROMODOMAIN_1; 1.
DR   PROSITE; PS50014; BROMODOMAIN_2; 1.
DR   PROSITE; PS51727; CBP_P300_HAT; 1.
DR   PROSITE; PS50952; KIX; 1.
DR   PROSITE; PS50134; ZF_TAZ; 2.
DR   PROSITE; PS01357; ZF_ZZ_1; 1.
DR   PROSITE; PS50135; ZF_ZZ_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Acyltransferase; Biological rhythms;
KW   Bromodomain; Cell cycle; Chromosomal rearrangement; Citrullination;
KW   Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Disease mutation; Host-virus interaction; Isopeptide bond;
KW   Metal-binding; Methylation; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Transcription; Transcription regulation;
KW   Transferase; Ubl conjugation; Zinc; Zinc-finger.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895}.
FT   CHAIN         2   2414       Histone acetyltransferase p300.
FT                                /FTId=PRO_0000211193.
FT   DOMAIN      566    645       KIX. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00311}.
FT   DOMAIN     1067   1139       Bromo. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00035}.
FT   DOMAIN     1287   1663       CBP/p300-type HAT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01065}.
FT   ZN_FING     331    417       TAZ-type 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00203}.
FT   ZN_FING    1664   1707       ZZ-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00228}.
FT   ZN_FING    1728   1809       TAZ-type 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00203}.
FT   REGION        2    149       Interaction with RORA.
FT                                {ECO:0000269|PubMed:9862959}.
FT   REGION        2    139       Interaction with ALX1.
FT                                {ECO:0000269|PubMed:12929931}.
FT   REGION     1017   1029       CRD1; mediates transcriptional
FT                                repression.
FT   REGION     1397   1399       Interaction with histone.
FT                                {ECO:0000269|PubMed:18273021}.
FT   REGION     1398   1400       Acetyl-CoA binding.
FT                                {ECO:0000269|PubMed:24819397}.
FT   REGION     1410   1411       Acetyl-CoA binding.
FT                                {ECO:0000269|PubMed:24819397}.
FT   REGION     1572   1818       Binding region for E1A adenovirus.
FT   REGION     2003   2212       Interaction with HTLV-1 Tax.
FT   REGION     2041   2240       Interaction with NCOA2.
FT                                {ECO:0000269|PubMed:15731352}.
FT   MOTIF        11     17       Nuclear localization signal.
FT                                {ECO:0000255}.
FT   COMPBIAS    797    800       Poly-Ser.
FT   COMPBIAS   1519   1526       Poly-Glu.
FT   COMPBIAS   2066   2069       Poly-Gln.
FT   COMPBIAS   2190   2195       Poly-Gln.
FT   METAL       347    347       Zinc 1.
FT   METAL       351    351       Zinc 1.
FT   METAL       364    364       Zinc 1.
FT   METAL       369    369       Zinc 1.
FT   METAL       378    378       Zinc 2.
FT   METAL       382    382       Zinc 2.
FT   METAL       388    388       Zinc 2.
FT   METAL       393    393       Zinc 2.
FT   METAL       402    402       Zinc 3.
FT   METAL       406    406       Zinc 3.
FT   METAL       411    411       Zinc 3.
FT   METAL       414    414       Zinc 3.
FT   BINDING    1457   1457       Acetyl-CoA; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:24819397}.
FT   BINDING    1462   1462       Acetyl-CoA.
FT                                {ECO:0000269|PubMed:24819397}.
FT   BINDING    1466   1466       Acetyl-CoA.
FT                                {ECO:0000269|PubMed:24819397}.
FT   SITE         31     32       Breakpoint for translocation to form
FT                                KAT6A-EP300 and EP300-KAT6A.
FT   SITE       2088   2088       Interaction with NCOA2.
FT   SITE       2142   2142       Interaction with NCOA2.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895}.
FT   MOD_RES      89     89       Phosphoserine; by AMPK.
FT                                {ECO:0000269|PubMed:11518699,
FT                                ECO:0000269|PubMed:16574662}.
FT   MOD_RES     418    418       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:18995842}.
FT   MOD_RES     423    423       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:18995842}.
FT   MOD_RES     499    499       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:B2RWS6}.
FT   MOD_RES     580    580       Omega-N-methylated arginine; by CARM1.
FT                                {ECO:0000269|PubMed:11701890}.
FT   MOD_RES     604    604       Omega-N-methylated arginine; by CARM1.
FT                                {ECO:0000269|PubMed:11701890}.
FT   MOD_RES     636    636       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     977    977       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1020   1020       N6-acetyllysine; alternate.
FT                                {ECO:0000269|PubMed:15632193}.
FT   MOD_RES    1024   1024       N6-acetyllysine; alternate.
FT                                {ECO:0000269|PubMed:15632193}.
FT   MOD_RES    1038   1038       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1180   1180       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:B2RWS6}.
FT   MOD_RES    1336   1336       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:17065153}.
FT   MOD_RES    1473   1473       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:17065153}.
FT   MOD_RES    1499   1499       N6-acetyllysine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15004546}.
FT   MOD_RES    1542   1542       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861,
FT                                ECO:0000269|PubMed:18995842}.
FT   MOD_RES    1546   1546       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861,
FT                                ECO:0000269|PubMed:18995842}.
FT   MOD_RES    1549   1549       N6-acetyllysine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15004546,
FT                                ECO:0000269|PubMed:18995842}.
FT   MOD_RES    1554   1554       N6-acetyllysine; by autocatalysis.
FT                                {ECO:0000244|PubMed:19608861,
FT                                ECO:0000269|PubMed:15004546}.
FT   MOD_RES    1555   1555       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1558   1558       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861,
FT                                ECO:0000269|PubMed:15004546}.
FT   MOD_RES    1560   1560       N6-acetyllysine; by autocatalysis.
FT                                {ECO:0000244|PubMed:19608861,
FT                                ECO:0000269|PubMed:15004546}.
FT   MOD_RES    1583   1583       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1699   1699       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:18995842}.
FT   MOD_RES    1704   1704       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:18995842}.
FT   MOD_RES    1707   1707       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:18995842}.
FT   MOD_RES    1726   1726       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2142   2142       Asymmetric dimethylarginine; by CARM1;
FT                                alternate. {ECO:0000269|PubMed:15731352}.
FT   MOD_RES    2142   2142       Citrulline; by PADI4; alternate.
FT                                {ECO:0000269|PubMed:15731352}.
FT   CROSSLNK   1020   1020       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO);
FT                                alternate.
FT   CROSSLNK   1024   1024       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO);
FT                                alternate.
FT   VARIANT     289    289       M -> V (in dbSNP:rs2230111).
FT                                /FTId=VAR_055554.
FT   VARIANT     827    827       L -> P (in a breast cancer sample).
FT                                {ECO:0000269|PubMed:10700188}.
FT                                /FTId=VAR_014428.
FT   VARIANT     997    997       I -> V (in dbSNP:rs20551).
FT                                /FTId=VAR_020425.
FT   VARIANT    1013   1013       E -> G (in a breast cancer sample).
FT                                {ECO:0000269|PubMed:10700188}.
FT                                /FTId=VAR_014429.
FT   VARIANT    1511   1511       N -> I. {ECO:0000269|PubMed:24476420}.
FT                                /FTId=VAR_074021.
FT   VARIANT    1650   1650       S -> Y (in a pancreatic cancer sample).
FT                                {ECO:0000269|PubMed:10700188}.
FT                                /FTId=VAR_014430.
FT   VARIANT    2174   2174       T -> S (in dbSNP:rs5758252).
FT                                /FTId=VAR_038376.
FT   VARIANT    2221   2221       P -> Q (in a colorectal cancer sample;
FT                                dbSNP:rs28937578).
FT                                {ECO:0000269|PubMed:10700188}.
FT                                /FTId=VAR_014431.
FT   VARIANT    2223   2223       Q -> P (in dbSNP:rs1046088).
FT                                {ECO:0000269|PubMed:7523245}.
FT                                /FTId=VAR_038377.
FT   MUTAGEN      89     89       S->A: Abolishes AMPK-mediated
FT                                phosphorylation.
FT                                {ECO:0000269|PubMed:11518699}.
FT   MUTAGEN      89     89       S->D: Phosphomimetic mutant that leads to
FT                                descreased interaction with nuclear
FT                                receptors. {ECO:0000269|PubMed:11518699}.
FT   MUTAGEN     344    344       L->A: Inhibits interaction with HIF1A and
FT                                transcription activation; when associated
FT                                with A-345.
FT                                {ECO:0000269|PubMed:12778114}.
FT   MUTAGEN     345    345       L->A: Inhibits interaction with HIF1A and
FT                                transcription activation; when associated
FT                                with A-344.
FT                                {ECO:0000269|PubMed:12778114}.
FT   MUTAGEN     371    376       TMKNVL->NAAIRS: Inhibits interaction with
FT                                HIF1A. Reduces interaction with CITED2.
FT                                {ECO:0000269|PubMed:9887100}.
FT   MUTAGEN     413    418       VCLPLK->NAAIRS: Inhibits interaction with
FT                                HIF1A. Does not inhibit interaction with
FT                                CITED2. {ECO:0000269|PubMed:9887100}.
FT   MUTAGEN    1020   1020       K->A: Abolishes sumoylation and
FT                                transcriptional repression when
FT                                associated with A-1024.
FT                                {ECO:0000269|PubMed:12718889,
FT                                ECO:0000269|PubMed:15632193}.
FT   MUTAGEN    1020   1020       K->R: Abolishes sumoylation and
FT                                transcriptional repression; when
FT                                associated with R-1024.
FT                                {ECO:0000269|PubMed:12718889,
FT                                ECO:0000269|PubMed:15632193}.
FT   MUTAGEN    1024   1024       K->A: Abolishes sumoylation and
FT                                transcriptional repression; when
FT                                associated with A-1020.
FT                                {ECO:0000269|PubMed:12718889,
FT                                ECO:0000269|PubMed:15632193}.
FT   MUTAGEN    1024   1024       K->R: Abolishes sumoylation and
FT                                transcriptional repression; when
FT                                associated with R-1020.
FT                                {ECO:0000269|PubMed:12718889,
FT                                ECO:0000269|PubMed:15632193}.
FT   MUTAGEN    1170   1170       F->E: Increased acetyltransferase
FT                                activity. {ECO:0000269|PubMed:23934153}.
FT   MUTAGEN    1204   1204       C->R: Increased acetyltransferase
FT                                activity. {ECO:0000269|PubMed:23934153}.
FT   MUTAGEN    1242   1242       E->K: Increased acetyltransferase
FT                                activity. {ECO:0000269|PubMed:23934153}.
FT   MUTAGEN    1357   1357       T->L: 40% decrease in activity.
FT                                {ECO:0000269|PubMed:18273021}.
FT   MUTAGEN    1357   1357       T->R: 40% decrease in activity. 90%
FT                                decrease in activity; when associated
FT                                with R-1505; R-1625 and R-1628.
FT                                {ECO:0000269|PubMed:18273021}.
FT   MUTAGEN    1396   1396       S->R: Loss of activity; when associated
FT                                with R-1397.
FT                                {ECO:0000269|PubMed:18273021}.
FT   MUTAGEN    1396   1396       S->W: Loss of activity; when associated
FT                                with W-1396.
FT                                {ECO:0000269|PubMed:18273021}.
FT   MUTAGEN    1397   1397       Y->R: Loss of activity; when associated
FT                                with R-1396.
FT                                {ECO:0000269|PubMed:18273021}.
FT   MUTAGEN    1397   1397       Y->W: Loss of activity; when associated
FT                                with W-1397.
FT                                {ECO:0000269|PubMed:18273021}.
FT   MUTAGEN    1399   1399       D->Y: Abolishes autoacetylation. Does not
FT                                interact with TFAP2A and inhibits
FT                                transcriptional coactivation of TFAP2A by
FT                                CITED2. Does not inhibit interaction with
FT                                CITED2, DNA-binding of TFAP2A or nuclear
FT                                localization of TFAP2A or CITED2. No
FT                                enhancement of FOXO1-mediated
FT                                transcriptional activity. No inhibition
FT                                of insulin-mediated translocation to the
FT                                cytoplasm. {ECO:0000269|PubMed:12586840,
FT                                ECO:0000269|PubMed:15890677,
FT                                ECO:0000269|PubMed:23934153}.
FT   MUTAGEN    1467   1467       Y->F: Abolishes autoacetylation. Loss of
FT                                acetyltransferase activity.
FT                                {ECO:0000269|PubMed:23934153}.
FT   MUTAGEN    1505   1505       E->R: 90% decrease in activity; when
FT                                associated with R-1625 and R-1628. 90%
FT                                decrease in activity; when associated
FT                                with R-1357; R-1625 and R-1628.
FT                                {ECO:0000269|PubMed:18273021}.
FT   MUTAGEN    1625   1625       D->R: 70% decrease in activity; when
FT                                associated with R-1628. 90% decrease in
FT                                activity; when associated with R-1505 and
FT                                R-1628. 90% decrease in activity; when
FT                                associated with R-1357; R-1505 and R-
FT                                1628. {ECO:0000269|PubMed:18273021}.
FT   MUTAGEN    1628   1628       D->R: 70% decrease in activity; when
FT                                associated with R-1625. 90% decrease in
FT                                activity; when associated with E-1505 and
FT                                R-1625. 90% decrease in activity; when
FT                                associated with R-1357; R-1505 and R-
FT                                1625. {ECO:0000269|PubMed:18273021}.
FT   MUTAGEN    1645   1646       RR->EE: Increased acetyltransferase
FT                                activity. {ECO:0000269|PubMed:23934153}.
FT   MUTAGEN    2056   2056       R->K: No effect on interaction with
FT                                NCOA2. {ECO:0000269|PubMed:15731352}.
FT   MUTAGEN    2088   2088       R->K: Abolishes interaction with NCOA2.
FT                                {ECO:0000269|PubMed:15731352}.
FT   MUTAGEN    2142   2142       R->K: Strongly reduces interaction with
FT                                NCOA2. {ECO:0000269|PubMed:15731352}.
FT   CONFLICT    169    169       M -> T (in Ref. 1; AAA18639).
FT                                {ECO:0000305}.
FT   CONFLICT    204    204       N -> D (in Ref. 1; AAA18639).
FT                                {ECO:0000305}.
FT   CONFLICT    928    928       T -> N (in Ref. 1; AAA18639).
FT                                {ECO:0000305}.
FT   CONFLICT   1924   1924       A -> T (in Ref. 1; AAA18639).
FT                                {ECO:0000305}.
FT   HELIX       332    334       {ECO:0000244|PDB:1L3E}.
FT   HELIX       335    355       {ECO:0000244|PDB:1L3E}.
FT   TURN        356    358       {ECO:0000244|PDB:1L3E}.
FT   HELIX       367    379       {ECO:0000244|PDB:1L3E}.
FT   STRAND      386    389       {ECO:0000244|PDB:1L3E}.
FT   HELIX       391    405       {ECO:0000244|PDB:1L3E}.
FT   STRAND      408    410       {ECO:0000244|PDB:1P4Q}.
FT   HELIX       414    418       {ECO:0000244|PDB:1L3E}.
FT   HELIX      1051   1066       {ECO:0000244|PDB:5BT3}.
FT   TURN       1069   1072       {ECO:0000244|PDB:5BT3}.
FT   HELIX      1073   1075       {ECO:0000244|PDB:5BT3}.
FT   HELIX      1081   1084       {ECO:0000244|PDB:5BT3}.
FT   HELIX      1089   1092       {ECO:0000244|PDB:5BT3}.
FT   HELIX      1099   1107       {ECO:0000244|PDB:5BT3}.
FT   HELIX      1114   1131       {ECO:0000244|PDB:5BT3}.
FT   HELIX      1137   1160       {ECO:0000244|PDB:5BT3}.
FT   STRAND     1180   1182       {ECO:0000244|PDB:5LKX}.
FT   STRAND     1189   1194       {ECO:0000244|PDB:5LKT}.
FT   TURN       1195   1197       {ECO:0000244|PDB:5LKT}.
FT   STRAND     1198   1201       {ECO:0000244|PDB:5LKT}.
FT   HELIX      1202   1207       {ECO:0000244|PDB:5LKT}.
FT   STRAND     1210   1215       {ECO:0000244|PDB:5LKT}.
FT   STRAND     1218   1221       {ECO:0000244|PDB:4BHW}.
FT   STRAND     1224   1227       {ECO:0000244|PDB:5LKT}.
FT   HELIX      1228   1230       {ECO:0000244|PDB:5LKT}.
FT   STRAND     1231   1236       {ECO:0000244|PDB:5LKT}.
FT   STRAND     1244   1246       {ECO:0000244|PDB:5LKT}.
FT   TURN       1248   1250       {ECO:0000244|PDB:5LKT}.
FT   STRAND     1253   1255       {ECO:0000244|PDB:5LKT}.
FT   HELIX      1256   1259       {ECO:0000244|PDB:5LKT}.
FT   TURN       1263   1265       {ECO:0000244|PDB:5LKT}.
FT   HELIX      1273   1278       {ECO:0000244|PDB:5LKT}.
FT   HELIX      1297   1313       {ECO:0000244|PDB:3BIY}.
FT   STRAND     1321   1334       {ECO:0000244|PDB:3BIY}.
FT   HELIX      1339   1342       {ECO:0000244|PDB:3BIY}.
FT   TURN       1343   1347       {ECO:0000244|PDB:3BIY}.
FT   STRAND     1351   1366       {ECO:0000244|PDB:3BIY}.
FT   STRAND     1369   1381       {ECO:0000244|PDB:3BIY}.
FT   STRAND     1392   1400       {ECO:0000244|PDB:3BIY}.
FT   HELIX      1407   1409       {ECO:0000244|PDB:3BIY}.
FT   HELIX      1410   1428       {ECO:0000244|PDB:3BIY}.
FT   STRAND     1432   1436       {ECO:0000244|PDB:3BIY}.
FT   STRAND     1446   1450       {ECO:0000244|PDB:3BIY}.
FT   HELIX      1460   1476       {ECO:0000244|PDB:3BIY}.
FT   STRAND     1482   1485       {ECO:0000244|PDB:3BIY}.
FT   HELIX      1486   1493       {ECO:0000244|PDB:3BIY}.
FT   HELIX      1498   1500       {ECO:0000244|PDB:3BIY}.
FT   HELIX      1508   1517       {ECO:0000244|PDB:3BIY}.
FT   HELIX      1582   1590       {ECO:0000244|PDB:3BIY}.
FT   HELIX      1592   1594       {ECO:0000244|PDB:3BIY}.
FT   STRAND     1595   1601       {ECO:0000244|PDB:3BIY}.
FT   HELIX      1603   1606       {ECO:0000244|PDB:3BIY}.
FT   HELIX      1622   1624       {ECO:0000244|PDB:3BIY}.
FT   STRAND     1625   1627       {ECO:0000244|PDB:3BIY}.
FT   HELIX      1628   1636       {ECO:0000244|PDB:3BIY}.
FT   HELIX      1644   1662       {ECO:0000244|PDB:3BIY}.
FT   TURN       1726   1728       {ECO:0000244|PDB:2MZD}.
FT   HELIX      1730   1747       {ECO:0000244|PDB:3T92}.
FT   HELIX      1756   1770       {ECO:0000244|PDB:3T92}.
FT   TURN       1774   1778       {ECO:0000244|PDB:3T92}.
FT   HELIX      1780   1793       {ECO:0000244|PDB:3T92}.
FT   STRAND     1799   1802       {ECO:0000244|PDB:2MZD}.
FT   HELIX      1806   1818       {ECO:0000244|PDB:3T92}.
SQ   SEQUENCE   2414 AA;  264161 MW;  8E869E1F174A6FEB CRC64;
     MAENVVEPGP PSAKRPKLSS PALSASASDG TDFGSLFDLE HDLPDELINS TELGLTNGGD
     INQLQTSLGM VQDAASKHKQ LSELLRSGSS PNLNMGVGGP GQVMASQAQQ SSPGLGLINS
     MVKSPMTQAG LTSPNMGMGT SGPNQGPTQS TGMMNSPVNQ PAMGMNTGMN AGMNPGMLAA
     GNGQGIMPNQ VMNGSIGAGR GRQNMQYPNP GMGSAGNLLT EPLQQGSPQM GGQTGLRGPQ
     PLKMGMMNNP NPYGSPYTQN PGQQIGASGL GLQIQTKTVL SNNLSPFAMD KKAVPGGGMP
     NMGQQPAPQV QQPGLVTPVA QGMGSGAHTA DPEKRKLIQQ QLVLLLHAHK CQRREQANGE
     VRQCNLPHCR TMKNVLNHMT HCQSGKSCQV AHCASSRQII SHWKNCTRHD CPVCLPLKNA
     GDKRNQQPIL TGAPVGLGNP SSLGVGQQSA PNLSTVSQID PSSIERAYAA LGLPYQVNQM
     PTQPQVQAKN QQNQQPGQSP QGMRPMSNMS ASPMGVNGGV GVQTPSLLSD SMLHSAINSQ
     NPMMSENASV PSLGPMPTAA QPSTTGIRKQ WHEDITQDLR NHLVHKLVQA IFPTPDPAAL
     KDRRMENLVA YARKVEGDMY ESANNRAEYY HLLAEKIYKI QKELEEKRRT RLQKQNMLPN
     AAGMVPVSMN PGPNMGQPQP GMTSNGPLPD PSMIRGSVPN QMMPRITPQS GLNQFGQMSM
     AQPPIVPRQT PPLQHHGQLA QPGALNPPMG YGPRMQQPSN QGQFLPQTQF PSQGMNVTNI
     PLAPSSGQAP VSQAQMSSSS CPVNSPIMPP GSQGSHIHCP QLPQPALHQN SPSPVPSRTP
     TPHHTPPSIG AQQPPATTIP APVPTPPAMP PGPQSQALHP PPRQTPTPPT TQLPQQVQPS
     LPAAPSADQP QQQPRSQQST AASVPTPTAP LLPPQPATPL SQPAVSIEGQ VSNPPSTSST
     EVNSQAIAEK QPSQEVKMEA KMEVDQPEPA DTQPEDISES KVEDCKMEST ETEERSTELK
     TEIKEEEDQP STSATQSSPA PGQSKKKIFK PEELRQALMP TLEALYRQDP ESLPFRQPVD
     PQLLGIPDYF DIVKSPMDLS TIKRKLDTGQ YQEPWQYVDD IWLMFNNAWL YNRKTSRVYK
     YCSKLSEVFE QEIDPVMQSL GYCCGRKLEF SPQTLCCYGK QLCTIPRDAT YYSYQNRYHF
     CEKCFNEIQG ESVSLGDDPS QPQTTINKEQ FSKRKNDTLD PELFVECTEC GRKMHQICVL
     HHEIIWPAGF VCDGCLKKSA RTRKENKFSA KRLPSTRLGT FLENRVNDFL RRQNHPESGE
     VTVRVVHASD KTVEVKPGMK ARFVDSGEMA ESFPYRTKAL FAFEEIDGVD LCFFGMHVQE
     YGSDCPPPNQ RRVYISYLDS VHFFRPKCLR TAVYHEILIG YLEYVKKLGY TTGHIWACPP
     SEGDDYIFHC HPPDQKIPKP KRLQEWYKKM LDKAVSERIV HDYKDIFKQA TEDRLTSAKE
     LPYFEGDFWP NVLEESIKEL EQEEEERKRE ENTSNESTDV TKGDSKNAKK KNNKKTSKNK
     SSLSRGNKKK PGMPNVSNDL SQKLYATMEK HKEVFFVIRL IAGPAANSLP PIVDPDPLIP
     CDLMDGRDAF LTLARDKHLE FSSLRRAQWS TMCMLVELHT QSQDRFVYTC NECKHHVETR
     WHCTVCEDYD LCITCYNTKN HDHKMEKLGL GLDDESNNQQ AAATQSPGDS RRLSIQRCIQ
     SLVHACQCRN ANCSLPSCQK MKRVVQHTKG CKRKTNGGCP ICKQLIALCC YHAKHCQENK
     CPVPFCLNIK QKLRQQQLQH RLQQAQMLRR RMASMQRTGV VGQQQGLPSP TPATPTTPTG
     QQPTTPQTPQ PTSQPQPTPP NSMPPYLPRT QAAGPVSQGK AAGQVTPPTP PQTAQPPLPG
     PPPAAVEMAM QIQRAAETQR QMAHVQIFQR PIQHQMPPMT PMAPMGMNPP PMTRGPSGHL
     EPGMGPTGMQ QQPPWSQGGL PQPQQLQSGM PRPAMMSVAQ HGQPLNMAPQ PGLGQVGISP
     LKPGTVSQQA LQNLLRTLRS PSSPLQQQQV LSILHANPQL LAAFIKQRAA KYANSNPQPI
     PGQPGMPQGQ PGLQPPTMPG QQGVHSNPAM QNMNPMQAGV QRAGLPQQQP QQQLQPPMGG
     MSPQAQQMNM NHNTMPSQFR DILRRQQMMQ QQQQQGAGPG IGPGMANHNQ FQQPQGVGYP
     PQQQQRMQHH MQQMQQGNMG QIGQLPQALG AEAGASLQAY QQRLLQQQMG SPVQPNPMSP
     QQHMLPNQAQ SPHLQGQQIP NSLSNQVRSP QPVPSPRPQS QPPHSSPSPR MQPQPSPHHV
     SPQTSSPHPG LVAAQANPME QGHFASPDQN SMLSQLASNP GMANLHGASA TDLGLSTDNS
     DLNSNLSQST LDIH
//
